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p53 is mutated in 50% of all human cancers, and up to 70% of lung cancer. Mutant p53
is usually expressed at elevated levels in cancer cells and has been correlated with a poor
prognosis. Cancer cells that express mutant p53 show an increase in oncogenic phenotypes
including an increase in growth rate, resistance to chemotherapeutic drugs, and an increase in
motility and tumorigenicity to name a few. We have identified several genes involved in cell
growth and survival that are upregulated by expression of common p53 mutants: NFκB2, Axl,
and epidermal growth factor receptor (EGFR). The aim of this study was to determine the role
NFκB2, Axl, and EGFR play in mutant p53’s gain of function (GOF) phenotype and to
determine a mechanism for upregulation of mutant p53 target gene upregulation.
Inhibition of mutant p53 in various cancer cell lines using RNAi in the form of transient
siRNA transfection or stable shRNA cell line generation caused a decrease in the gain of

function ability of those cells in the form of reduced chemoresistance, reduced cell growth and
motility, and a reduction in tumor formation. Additionally, inhibition of NFκB2, Axl, and EGFR
also showed similar effects. Promoter deletion analysis of the NFκB2 promoter did not show a
specific mutant p53 response element needed for mutant p53 mediated transactivation.
Similarly, deletion of the p53/p63 binding site on the Axl promoter did not inhibit mutant p53
transactivation. Sequence analysis of the NFκB2, Axl, and EGFR promoters revealed several
transcription factor binding sites located throughout the promoters. ChIP analysis of mutant p53
and the promoter-specific transcription factor binding revealed that in the presence of mutant
p53, individual transcription factor binding is increased to the NFκB2, Axl, and EGFR promoters
as well as an increase in acetylated histone binding. This data suggests that mutant p53 promotes
an increase in transcription by inducing acetylation of histones via recruitment of transcription
factors to the promoters of mutant p53 target genes.

Introduction

Discovery of p53. p53 was discovered in 1979 by five independent groups when it
coprecipitated with the large T antigen in simian virus 40 (SV40) transformed hamster cells (16). It was later found in high concentrations in various cancerous and transformed cells (2, 5, 79). p53 was originally thought to behave as an oncogene when co-transfection of mouse p53
cDNA with activated Ras transformed rat embryonic fibroblasts (REF), however it was later
learned that the p53 cDNA clone used contained a mutation (10-12). Afterwards, co-transfection
of wild-type (WT) p53 cDNA with activated Ras reduced the transformation potential of REFs
and even inhibited the transformation potential when a known oncogene was added as well,
leading to the belief that p53 acts as a repressor of cellular transformation (13, 14). The role of
p53 in tumor formation was later investigated through the creation of a mouse model system
where one or both alleles of p53 were deleted, or left as wild-type. p53 was shown to behave as
a tumor suppressor when the majority of p53 null mice formed tumors by six months of age
while WT mice showed very little tumor onset when aged three times as long (15).
Structure and function of p53. The p53 gene is located on the short arm of
chromosome 17 and is a phosphoprotein that is localized mainly in the nucleus (16, 17). It exists
as an oligomer but mainly as a tetramer in the cell and binds to DNA sequence-specifically (1821). Not only is p53 a transcriptional activator, it can also repress transcription (22-27). The p53
consensus sequence is defined as two half-sites of 5’-PuPuPuCWWGPyPyPy-3’ (Pu indicates a
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purine base, Py indicates a pyrimidine base, and W indicates either adenine or thymine) that are
separated by 0-13 bases (28).
p53 is a 393 amino acid long protein with a well-established structure-function
relationship. The protein contains five functional domains: the transactivation domain (TAD,
amino acids 1-92) contains both TADI (aa1-42) and TADII (aa43-92), the proline rich domain
(aa64-92), the DNA binding domain (aa101-300), an oligomerization domain (aa307-355), and a
C-terminal regulatory domain (aa356-393) (29-39) (Figure 1). There are five highly conserved
domains among p53 genes from evolutionarily distant species, the first is located within the first
transactivation domain, and the remaining four are found within the DNA binding domain (40,
41).
WT p53 is activated in response to a variety of stressors including DNA damage, heat
shock, and hypoxia to name a few. Upon activation, p53 stabilizes and either causes transient or
permanent (senescence) cell cycle arrest, activates DNA repair, or initiates apoptosis (Figure 2)
(42-47). WT p53 is a transcription factor that activates a large group of genes whose regulatory
sequences have p53 consensus binding sites. (48, 49). Although WT p53 has biological activities
that are transcription independent, the majority of its functions are dependent on its
transcriptional ability (50). WT p53 has been shown to be involved in many biological activities
including aging (51), DNA damage response (52), autophagy (53), maintenance of genetic
stability (54), metabolism (55), miRNA transcription (56), and stem cell fate determination (57),
amongst others.
p53 regulation. The tumor suppressor p53 is highly unstable due to its short half-life
(21). Under normal circumstances WT p53 is regulated via interaction with mouse double
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Figure 1. Schematic of p53 protein indicating several mutations within the DNA binding
domain.
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Figure 2. Simplified cartoon for the activation of WT p53 and its major functions.
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minute 2 (MDM2) (58, 59). MDM2 binds to p53 at the N-terminus, blocking transcriptional
activity, and promotes p53 degradation by transporting it from the nucleus to the cytosol where it
is marked for ubiquitination (58-65). When cell stress or DNA damage activates p53 it is
phosphorylated at several sites within the N-terminus which free it from MDM2, abrogating
ubiquitination, leading to p53 stabilization and accumulation (66, 67).
Another pathway that regulates p53 is the PI3K/Akt pathway. Akt has been shown to
phosphorylate MDM2 which translocates MDM2 to the nucleus where it targets p53 for
ubiqutination (68-73). p53 acetylation has also been shown to increase the stability of the
protein, leading to increased transcriptional activity due to an open conformation. This can be
accomplished through histone acetyltransferases (HATs) such as p300/CBP/PCAF or alternately,
a decrease in histone deacetylases such as HDAC1 OR SIRT1 (74-78).
Transcription by WT p53. WT p53 mediated transactivation occurs when p53 binds to its
consensus site on the DNA and assembles HATs to contact the RNA polymerase II complex at
the site of transcription initiation via TBP associated factors (79, 80). WT p53 was also shown
to function as a transcriptional repressor in the early 90's when it was shown to inhibit
transcription from a number of cellular and viral promoters (27, 81). Repression of transcription
by p53 can be either direct or indirect. Direct transcriptional repression could happen by p53
binding to its consensus site within the regulatory region of the genes it regulates which
competitively inhibiting other activating transcription factors (82). p53 has also been shown to
bind to its site on the regulatory sequences of genes and recruit co-repressors such as mSin3A,
which inhibits HATs and thereby represses transcription (83).
p53 mutations. p53 is the most frequently mutated gene in human cancer with
approximately 50% of all human cancers carrying a mutation in the p53 protein (84-87). The
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majority (73%) of mutations that have been discovered within p53 are considered missense
mutations that are located within the DNA binding domain (http://p53.iarc.fr/) (88, 89). In most
human tumors only the mutant protein is expressed; usually one allele is point mutated and the
other allele is deleted (85-87, 90, 91). The IARC database defines "hot spot" mutations as
mutations that represent at least 20% of all reported p53 mutations, which include mutations at
codons 175, 245, 248, 273, and 282 (89, 92, 93). Mutations of p53 are classified as those that
either affect protein-DNA contact (Class I, i.e. R273H), or alter the protein conformation (Class
II, i.e. R175H) (94-96).
Types of p53 mutations. p53 mutations found in human cancer can be divided into three
categories: (1) Loss of function mutations. These mutations are responsible for the loss of the
tumor suppressor function of p53. Almost all of the p53 mutants that have been identified are
categorized as loss of function mutations. In general, they are defective in sequence-specific
transactivation of genes containing WT p53 consensus binding sites. (2) Dominant negative
mutations. Hetero-oligomeric complex formation between mutant p53 and WT p53 causes
changes in the properties of WT p53, with the mutant becoming dominant over the WT protein’s
properties, therefore inactivating its tumor suppressor functions. An example of this is the
immortalization and transformation of rodent embryo fibroblasts by mutant p53 (9, 97). This is
thought to cause the increased cancer susceptibility of patients with Li-Fraumeni syndrome as
well as p53 +/- mice (98). (3) Gain of function (GOF) mutations. In this case, mutant p53
acquires a dominant oncogenic role that does not depend on complex formation with WT p53.
An example of this would be expression of mutant p53 in cells where WT p53 is absent which
show enhanced oncogenic properties compared to p53-null cells.
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Gain-of-Function mutant p53. Mutations that are characterized as GOF mutations not
only lose the WT tumor suppressor function, but also gain new oncogenic functions.
Overexpression of mutant p53 in a large number of human cancers not only distinguishes it from
other tumor suppressors, but also suggests that there is a selective pressure behind its
accumulation. Expression of mutant p53 in cells lacking p53 altogether has been shown to
stimulate growth and carries a worse prognosis in patients (99-103). This also suggests that
tumors containing mutant p53 may be more aggressive than p53-null tumors.
Gain of function mutant p53 properties. Biological gain of function activity was
confirmed when expression of human mutant p53 in the 10(3) murine fibroblast cell line that is
endogenously p53-null, caused tumor formation in nude mice even though 10(3) cells alone or
10(3) (vector transfected) cells do not (100). Expression of mutant p53 has been shown to result
in oncogenic and proliferative processes such as increased tumorigenicity (100, 104, 105),
increased growth in soft agar (106), decreased sensitivity to chemotherapeutic drugs (107-110),
increased DNA synthesis and increased growth rate (111-116), induction of gene amplification
(117-119), induction of cellular motility, invasive capability and metastasis (120-125), increased
tumor angiogenesis (126), and promotion of chronic inflammation and associated cancer (127).
These phenotypes show that mutant p53 has a physiological role that leads to the aggressive
tumor development and poor prognosis.
Mouse models of mutant p53. Many groups have tried to use mouse models to
demonstrate the gain of function ability of mutant p53. An increased metastatic potential was
shown in mice inheriting knock-in p53-R172H (homologous to human p53-R175H) (128), and
evidence of gain-of-function associated with genomic instability was explored using transgenic
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p53-R172H mice (129). The necessity of stabilization for mutant p53 gain of function activity in
a mouse system by MDM2 or p16 knock out has also been demonstrated (130).
Mouse models of pancreatic cancer were used to show increased tumor formation and
metastases in the presence of mutant p53 versus loss of WT p53 (131, 132). The degree of GOF
between mutations was studied using knock-in mice expressing two different hot spot p53
mutations to investigate the difference in tumor formation and survival. A marked increase in
tumor formation and decrease in survival in mice expressing R248Q versus G245S was
ultimately found (133).
Transcription by mutant p53. p53 mutants have been shown by several groups to
upregulate genes involved in cell growth and oncogenesis through the use of microarray analysis
in cells overexpressing mutant p53 in a p53-null background (110, 134, 135). Mutant p53 has
also been demonstrated to repress expression of a number of genes including inhibitor of
differentiation (Id2) (136, 137) p21, gadd45, PERP and PTEN (137), among others. Some of
these genes are involved in pro-apoptotic activities, including CD95 (Fas/ApoI) (138, 139),
caspase-3 (140) and others (141, 142).
Mechanism of mutant p53 transactivation. There are two possible mechanisms to
explain transactivation by GOF mutant p53: one that involves its direct binding to DNA and
transcriptional modulation of gene expression, and one in which mutant p53 does not directly
come near regulatory sequences on the chromosome. This second category can be subdivided
further: (1) protein-protein interactions between mutant p53 and other cellular protein(s), such as
the p53 family members, p63 and p73, DNA machinery proteins, and/or proteins of the apoptotic
pathway (143, 144); (2) modulation of target genes by mutant p53 (Figure 2), such as activating

8

growth promoting genes, disrupting DNA repair or apoptotic activities or inhibiting growth
suppressive genes (138, 145-148).
As far as the first possible mechanism goes, there is evidence to show that GOF p53 does
in fact bind to DNA on the chromosome, particularly in G/C rich areas around transcription start
sites of some genes that are characterized by active chromatin marks (149-153).
As mentioned above, regulation of transcription by protein-protein interactions can be
either via interaction of mutant p53 with its family members p63 and/or p73, or through
interactions with transcription factors. The fact that p53 family members p63 and p73 retain the
capability of interacting with tumor-derived p53 mutants led to the possibility that such
interactions may inhibit p63/p73 function (147, 154-158). In this model, it is thought that mutant
p53 may inhibit p63/p73’s DNA binding ability by interacting with the DNA binding domain of
p63/p73, as model systems predict (155). Some of the GOF activities of mutant p53 assume that
mutant p53 would block the inhibitory effects of p63/p73 (mostly p63). However, transactivation
observed by GOF p53 cannot be explained by this model alone, since there are genes that are
transactivated by p63 as well as GOF p53 (159, 160). There is another model that is evolving
that involves mostly p63 (and perhaps p73), in which it is assumed that mutant p53 can anchor to
p63 and become nucleated on promoters with p63/p73 sites. There is evidence for this possibility
also (161).
It was proposed about 20 years ago that mutant p53 may transactivate genes it upregulates indirectly through interactions with transcription factors that normally bind to the
regulatory regions of those target genes (162-164). Various groups have shown interactions of
p53 (both WT and mutant) with several transcription factors including Sp1, E2F1, Ets1, CREB,
p300/CREBP, NFY-A (74, 113, 157, 164-168) and others. Although in some cases evidence has
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been presented that indicates nucleation of mutant p53 on DNA by anchoring onto another
transcription factor, in most cases there is a lack of clear-cut evidence. Overall it is assumed that
mutant p53 becomes situated on the promoter-regulatory sequence of a target gene by its
interaction with a transcription factor, and then through its intact transactivation domain it is able
to interact with the transcription initiation complex presumably near the transcription start site. It
is most likely that the transactivation domain interacts with the component of the “mediator”
complex (79, 169, 170). Also, it is generally assumed that mutant p53-CREBP/p300 interaction
would facilitate nucleation of these histone acetylases on the chromatin. This results in an
opening up of the chromatin by acetylation of histones (171, 172).
Addiction to GOF mutant p53. Oncogene addiction describes the situation where
cancer cells cannot function without the many chromosomal abnormalities that have accrued
within those cells (173). Knock-down of a particular protein that a cancer cell is addicted to can
cause the cell to cease functioning and apoptose, enter a slower growth phase, or growth arrest
(173). Many lung cancer cell lines with endogenous expression of different p53 mutants have
been tested for their addiction to mutant p53 expression; interestingly, the addiction seems to be
allele specific in some gain of function activities, although all the cell lines characteristically lose
their enhanced growth rate on elimination of GOF p53 (174). Understanding the mechanism
behind the addiction to mutant p53 and its GOF activity is of the utmost importance toward
improving cancer’s survival rate.
Future therapeutic potential. Reducing mutant p53 expression in various cell lines has
been shown to be an effective way to diminish cell growth, migration, and tumorigenicity.
Unfortunately, there is no way at present to inhibit the mutant form of p53 in a patient without
also targeting WT p53 in healthy cells. Several therapies have been proposed within the last few
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years that might prove to be useful. One such therapy would be through the use of peptides to
change the conformation of the mutant protein to that of WT (175). Another would be to restore
degradation of mutant p53 through the use of HDAC inhibitors (176, 177). Small molecule
inhibitors such as siRNA could be also be used to preferentially target the mutant protein while
leaving WT p53 intact. Since the goal of cancer research aims to discover what causes a cell to
become oncogenic in the hope of developing a way to cure the disease, understanding the
mechanism of gain of function is essential to be able to effectively target mutant p53 for cancer
therapy. It may be possible that due to the activation of different pathways a combination
treatment strategy will have to be used.
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Hypothesis

Major hypothesis. The main goal of pursuing cancer research is to eventually discover a
cure for the disease. Unfortunately, there is no method for targeting mutant p53 without also
causing harm to WT p53 in patient's cells. The next best approach would be to develop therapies
against mutant p53 target genes or to inhibit mutant p53-mediated upregulation of those genes.
Mutant p53 utilizes several target genes to accomplish its gain of function phenotypes of
increased cell growth, chemoresistance, and survival, but the molecular events that lead to cancer
with GOF p53's participation, and the mechanisms of how GOF p53’s transactivation is involved
in oncogenesis are unknown. Previous research has shown that a group of genes involved in
oncogenesis are upregulated by mutant p53 with differential requirements of the transactivation
domain. Knock-down of mutant p53 in several breast and lung cancer cell lines abolishes GOF
activity of mutant p53 indicating the potential of targeting mutant p53 for cancer therapy. ChIP
sequencing has shown that mutant p53 interacts with promoters of its target genes. Studies of
histone acetylation by chromatin immunoprecipitation-sequencing and gene expression show
that histones at mutant p53 target promoters are acetylated in the presence of mutant p53. The
major hypothesis is that targeting GOF p53 in cancer would substantially inhibit tumor growth
and that the gain-of-function phenotype exhibited by various cancer cells containing mutant p53
requires genes such as NFκB2, Axl, and epidermal growth factor receptor (EGFR), which are
required for cancer progression. The specific aims are designed to better understand the
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relationship between mutant p53 and these three target genes and to determine a mechanism for
mutant p53-mediated transactivation.

Specific aims.
The following are the specific aims: (1) Determine the role of gain-of-function mutant
p53 in NFkB2 transactivation, (2) Determine how mutant p53 utilizes receptor tyrosine kinase
Axl to accomplish its gain-of-function activity, and (3) Determine how up-regulation of
epidermal growth factor receptor (EGFR) affects addiction of lung cancer cells to gain-offunction mutant p53.
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Chapter 1
DETERMINE THE ROLE OF GAIN-OF-FUNCTION MUTANT P53 IN NFKB2
TRANSACTIVATION
The work presented in this chapter has been published in the Archives of Biochemistry and Biophysics
research journal (Arch Biochem Biophys. 2012 Feb 1;518(1):79-88.). Some chemoresistance assasys were
performed by Amber Heck and Amanda High and the motility assays were performed by Andrew Yeudall.

Introduction.
WT p53 induces apoptosis after DNA damage caused by cytotoxic drugs, and it appears
that a cell’s p53 mutational status may determine the efficacy of many of these drugs (107, 108,
178). It has been shown that mutant p53 expression (in cells devoid of WT p53) can lead to
decreased sensitivity to drugs such as doxorubicin, etoposide, cisplatin and others (107, 108).
This can be partially explained by an effect of mutant p53 on p73 and p63 (179, 180). In a
previous study, evidence was presented to show that part of this chemoresistance may also arise
as a result of up-regulation of p52/p100 NF-κB2 by mutant p53 (110).
The NF-κB family of transcription factors regulates expression of many genes involved
in growth, differentiation, survival, development and inflammation (181, 182). In mammals this
group has five members: Rel A (p65), Rel B, c-Rel, p50/p105 (NF-κB1) and p52/p100 (NF-κB2)
(183); the factors function primarily as p50/Rel or p52/Rel heterodimers, although they may also
function as different homo- and heterodimers. The NF-κB2 protein is synthesized as a p100
precursor that gets processed to p52 for more functional activities upon activation of the
pathway. p52 over-expression can lead to lymphocyte hyperplasia and transformation (184).
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Constitutive nuclear NF-κB activity has emerged as a hallmark for many human leukemias,
lymphomas, and several other cancers (185).
Inhibition of NF-κB sensitizes many tumor cells to death-inducing stimuli, including
chemotherapeutic agents (185-189). Thus, transactivation of NF-κB could be a crucial step by
which mutant p53 induces oncogenic progression. Activation of NF-κB appears to protect tumor
cells from apoptosis, through induction of anti-apoptotic genes (190, 191), while p52 overexpression has been shown to inhibit pro-apoptotic genes as well (192).
In this study, using a number of cancer cell lines expressing mutant p53, we show that
GOF activities are dependent on the p53 level. We also demonstrate that up-regulation of NFκB2 in H1299 lung cancer cells expressing mutant p53 is caused by changes in chromatin
structure on the NF-κB2 promoter, and increasing interaction of crucial transcription factors with
the promoter.

Materials and Methods.
Cell lines.

Five human lung cancer cells lines: H23 (p53-M246I, NSCLC),

H1048 (p53-R273C, SCLC), H1437 (p53-R267P, NSCLC), KNS-62 (p53-R249S, NSCLC),
H1299 (p53-null, NSCLC); two human breast cancer cell lines: MDA-MB-468 (p53-R273H) and
SK-BR-3 (p53-R175H); and a human melanoma cell line MDA-MB-435 (p53-G266E) were
used in these studies, and grown in media prescribed by ATCC.
Generation of stable cell lines. Stable cell lines were generated after transfection of
p53-null H1299 lung carcinoma cells with mutant p53 expression plasmids (or expression vector
alone), which contain a neomycin resistance gene as described (104). Mutant p53 knock down
cell lines were generated by using lentivirus expressing short hairpin RNA (shRNA) against p53
15

utilizing lentivirus systems (Open Biosystems) following the manufacturer protocol. Clones
were isolated using puromycin selection at 1-3 µg/ml.
Drug sensitivity assay. Drug sensitivity assays were carried out as described by us
earlier (112). In general, cancer cells expressing mutant p53 were plated at 10,000 cells/10cm
dish and treated with a final concentration of 1-6 uM etoposide (Sigma; St. Louis, MO);
concentration of the drug used depended on the cell lines used and preliminary earlier
experiments. In our hands different cell lines respond differently towards the same concentration
of etoposide as far as cell death is concerned as measured by colony formation assays. We have
done preliminary experiments where we used different concentrations of the drug to determine
the sensitivity for individual cell lines. These experiments dictated what concentration we
ultimately chose for the final experiment the data of which we have presented. For control, in
order to avoid over-crowding, we plated 1000 cells/10cm dish treated with DMSO vehicle. The
number of cells used per assay varies depending on the cell line, its plating efficiency of the cells
and sensitivity towards the chemotherapeutic drug under consideration; but for the same cell line
and experiment we used identical number of cells.
After drug/DMSO treatment, plates were washed and the media replaced. The surviving
cells were allowed to form colonies for 2-3 weeks with periodic changes of media. Colonies
were fixed with methanol, stained with methylene blue and counted as described earlier (193).
The percent survival was calculated by dividing the average number of drug-treated colonies by
the average number of DMSO-treated colonies and multiplying by 100. This was done for each
siRNA treatment, either si-control or si-p53. All experiments were done in triplicate, and
repeated multiple times. The error bars represent standard deviation from the average number of
colonies counted.
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Growth assay. Growth assays were carried out as described by us earlier with slight
modifications (110, 135). Cells were plated at 50,000 cells/6cm dish in triplicate for five time
points and harvested after incubation with trypsin and counted using a Coulter Counter
(Beckman). Multiple cell clones were used for each assay. All experiments were done in
triplicate, and repeated multiple times. The error bars represent standard deviation from the
triplicates.
PARP cleavage assay. To determine if p53 knock down results in apoptotic cell death,
we performed a transient infection with lentivirus expressing p53 shRNA (or GFP shRNA) to
knock down mutant p53 in H1048 lung cancer cells expressing mutant p53 and assess apoptosis
without selection. For the PARP Western blot experiments we used H1048 cells treated with
etoposide (9 uM) for 48 hours as a positive control for apoptosis. The assay was carried out
using an antibody from Cell Signalling.
Xenograft assay.

Nu/nu mice were used for the tumorigenicity studies.

For all

injections, 1x107 cells/250µl media were used. Mice were injected subcutaneously on the flanks
and tumors allowed to grow to a maximum size of 1cm, measuring periodically as described
before (17, 18). Three different clones of H1048 cells with mutant p53 levels reduced by shRNA
were used in comparison to two GFP shRNA control cell lines to rule out clonal variations.
siRNA transfection. Breast or lung cancer cells were nucleofected with siRNA directed
against a specific or non-specific gene (luciferase) using a nucleofector and a nucleofector kit
following the manufacturer’s protocol (Amaxa Inc.; Gaithersburg, MD). Sequences used were:
Control (C): 5’- CAU GUC AUG UGU CAC AUC ACT T -3’ and 5’-GAG AUG UGA CAC
AUG ACA UGT T -3’, p53: 5‘-GCA UGA ACC GGA GGC CCA UTT-3‘ and 5‘-AUG GGC
CUC CGG UUC AUG CTT-3‘ (162) and NF-κB2: 5’-GCC CUG AGU GCC UGG AUC UTT-
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3’ and 5’-CGG GAC UCA CGG ACC UAG ATT-3’. Twenty-four hours after nucleofection,
cells were trypsinized, counted, plated and then exposed to etoposide or DMSO as a control for
48h and colony formation assays performed as described above.
Chromatin immunoprecipitation.

Chromatin immunoprecipitations (ChIP) were

performed as described (135, 194). To crosslink protein and DNA, cell cultures were incubated
in 2% formaldehyde for 10min at ambient temperature and then 200mM glycine was added for a
further 10min.

Cells were washed in cold PBS, scraped and centrifuged. Pellets were

resuspended in lysis buffer containing 1% protease inhibitors and then sheared by multiple
passages through a 27.5 gauge needle followed by 25min of sonication on ice such that the
chromatin was fragmented to 500–2000 bp length. Following centrifugation, the protein content
of the supernatants was determined and equal amounts used for immunoprecipitation overnight
at 4ºC with gentle tilting with anti-acetylated histone H3 antibody or IgG as a control. Immune
complexes were captured using Protein A-agarose, then washed sequentially once in RIPA
buffer (150mM NaCl, 50mM Tris pH8, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40), once
in high salt buffer (500mM NaCl, 50mM Tris pH8, 0.1% SDS, 1% NP-40), twice in LiCl buffer
(250mM LiCl, 50mM Tris pH8, 0.5% sodium deoxycholate, 1% NP-40) then twice in TE buffer.
Protein-DNA complexes were eluted from beads in fresh elution buffer (20% SDS, 10mM DTT,
100mM NaHCO3), crosslinking was reversed overnight at 65ºC in the presence of NaCl, and
then samples were ethanol-precipitated. Following centrifugation, pellets were resuspended in
TE buffer and incubated sequentially with 10mg/ml RNase A (30min) and 20mg/ml proteinase K
(1h). Samples were phenol/cholorform-extracted, ethanol-precipitated, and the pellets washed in
70% ethanol, dried and resuspended in sterile water. Acetyl histone H3 Ab and normal rabbit
IgG (17-615) were from Millipore; CREB (sc-186), c-Rel (sc-272), NFkB p65 (sc-372), STAT2
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(sc-476), p53 DO1 (sc-126) and AcH4 K16 (sc-8662) were from Santa Cruz Biotechnology,
Santa Cruz, CA. Quantitative PCR (QPCR) was used to quantify precipitated NF-κB2 promoterspecific DNA segments. We have performed two sets of QPCR: one with NF-κB2 specific
primers and another with GAPDH specific primers. The second set of QPCR (with GAPDH) has
been done to normalize the NF-κB2 values as GAPDH expression remains unchanged by p53.
Primers used to analyze ChIP samples were: GAPDH F: 5’-GTC AAC GGA TTT GGT CGT
ATT-3’ and R: 5’-GAT CTC GCT CCT GGA AGA TGG-3’ and NF-κB2 F: 5’-GAG GGA
GGA GGG GGC TTA ACC C-3’ and R: 5’-CGG GAG GCC CTC GAC AGT CTA C-3’.
Luciferase reporter assays. H1299 cells were transfected in triplicate with 200ng of the
promoter-luciferase reporter constructs and 1µg of vector only (pCMV Bam) or p53 expression
plasmid for 48 hr (112). After transfection, cells were harvested and luciferase activity measured
using the Promega luciferase assay kit (#E1500, Promega, Madison, WI) according to the
manufacturer’s instructions. Cell extracts were normalized to each other based on total protein
concentration and luciferase activity detected using a Luminometer from Turner Designs.
Western blotting. Immunoblottings were carried out as described (110). NF-κB2 levels
were detected using an antibody from Upstate Biotechnology (#05-361; Charlottesville, VA).
Actin levels were detected using the AC-15 antibody (Sigma; St. Louis, MO), p53 was detected
using the p53 antibody PAb 1801, and Erk2 was detected using ERK2 (sc-154) antibody from
Santa Cruz Biotechnology. Westerns blots were developed by the ECL method (GE Healthcare;
Piscataway, NJ). SK-BR-3 blot was developed using Li-COR system as described by Sanka et
al. 2011 (194).
Migration assays. Cell migration was carried out using wound-healing (scratch) assays,
as previously described (195). Briefly, cells were trypsinized, plated in quadruplicate in 12-well
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cell culture plates and incubated at 37°C until cells were completely confluent. At this time, a
sterile pipette tip was used to scratch across the surface of the plate, removing the complete layer
of cells within the scratch area. Following cell removal, each well was washed once with PBS
and then replaced with growth medium. Immediately following, the width of the scratch was
measured at six specific points under a 5x objective using a light microscope and AxioVision
software (Carl Zeiss Microimaging, Thornwood, NY). Cells were incubated at 37°C from 2060h depending on the cell line under study, at which time the scratch width was measured at the
same position as at time 0.
Apoptosis-DNA Ladder Assay. H1048 cells stably expressing a shRNA against p53 or
GFP were used for this assay along with a positive control (U937 cells treated with
camptothecin, provided in the kit from Roche cat. # 11835246001). Two million cells were used
for preparation of DNA for each sample. Cells were lysed with the binding/lysis buffer, and the
lysate applied to filter tubes which contain glass fiber fleece to bind nucleic acids. Impurities are
removed by washing and DNA is eluted off of the columns. 2µg of each DNA sample was run
in a 1% agarose TBE gel and run at 70V until full separation of the positive control DNA ladder
was visible.

Experimental Results.
Reducing p53 levels by RNAi in cancer cells with mutant p53 lowers gain of function
activities. If mutant p53 expression in cancer cells induces GOF phenotypes such as increased
tumorigenicity, growth rate, chemoresistance and motility, we hypothesized that by reducing the
level of mutant p53 in those cells we should be able to see reduction of these properties.
Therefore, we wanted to test whether that principle holds using cancer cell lines expressing
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Figure 3. Reducing p53 levels in cancer cells with mutant p53 by RNAi lowers
chemoresistance. The indicated cells were transfected with control (si-luc or si-scrambled) or
p53-specific siRNA, treated with appropriate concentrations of etoposide for 48h depending on
the sensitivity of the cell line to the drug, and colony formation determined (upper panels) as
described in Materials and methods. Immunoblots show the efficacy of p53 siRNA treatment.
Erk2, GAPDH, or actin was used as a loading control (lower panels). Percent survival is shown
in the figures with error bars representing standard deviation from the average number of
colonies. The percent survival was calculated by dividing the average number of drug-treated
colonies by the average number of DMSO-treated colonies and multiplying by 100. Experiments
were done in triplicate and data shown are representative of multiple independent repeats.
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mutant p53. Figure 3 shows the results of colony formation assays performed with cell lines
MDA-MB-468, MDA-MB-435, H1048 and SK-Br-3, after treatment with etoposide or DMSO.
Cells were treated with the drug or DMSO for 48h after being nucleofected with siRNA specific
for p53 or control (scrambled or luciferase) as described in Materials and methods. The data
demonstrate that these cell lines become more chemosensitive when the mutant p53 level is
reduced; thus the p53 mutants in these cells show GOF activity.
Figure 4 shows growth assay data of cancer lines H23, H1048 and H1437 when their p53
levels were reduced by lentivirus infection expressing shp53, compared to shGFP controls. The
data indicate that reduction of mutant p53 level has a significant effect of reducing the growth
rate of H23, H1048 and H1437 lung cancer cells. Thus mutant p53 controls the rate of growth of
cancer cells expressing GOF mutant p53. We carried out a PARP cleavage assay (to detect
apoptosis), which showed no significant differences between the shGFP and shp53 lentivirus
infected H1048 cells (Figure 4D) suggesting slower proliferation instead of induction of
apoptosis. We have also performed a DNA degradation assay using H1048 cells expressing
shRNA for GFP or p53 to further detect apoptosis. The data shown in Figure 4E indicated that
while in the positive control we could see DNA ladder formation, H1048 cells (expressing
shRNA for GFP or p53) did not show any indication of ladder formation corroborating PARP
cleavage data. This conclusively shows that mutant p53 reduction in H1048 cells does not cause
apoptosis.
Another GOF phenotype of mutant p53 is an increase in cell motility. To determine the
relationship between mutant p53 and motility, we performed migration assays of KNS-62 and
H1437 lung cancer cells after their p53 levels were knocked down by lentivirus expressing p53
shRNA, compared to shGFP controls (Figure 5A). The data indicate that reduction of mutant
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Figure 4. p53 knock down causes a decrease in growth rate in cancer cell lines. A-C.
Mutant p53 levels were knocked down in three cancer cell lines by lentivirus expressing p53
shRNA as indicated and their growth rates measured in comparison to the corresponding cell
lines generated after infecting with lentivirus expressing GFP shRNA as described in Materials
and methods. Cells were harvested every other day and cell numbers were determined by
Coulter Counter. Error bars represent standard deviation between the average cell counts.
Experiments were done in triplicate, and data are representative of multiple independent repeats.
Immunoblots show the efficacy of p53 knock down. ERK2 was used as a loading control. D.
For the H1048 cells, we performed a PARP cleavage assay to check for caspase activation using
PARP antibody from Cell Signaling. E. Apoptosis DNA-Ladder assay of H1048 cells stably
transfected with shp53 (1) or shGFP (2). U937 cells after treatment with CAM (3) were used as
a positive control for apoptosis.
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p53 level decreases cell motility. Thus, mutant p53 contributes to the increased motility rate of
cancer cells expressing GOF mutant p53.
Figure 5B shows a tumorigenicity assay of H1048 lung cancer cells when their p53 levels
were knocked down by lentivirus expressing p53 shRNA, compared to shGFP controls. The data
indicate that inhibiting mutant p53 expression leads to a reduction in tumor growth rate. Thus
mutant p53 controls the rate of tumorigenicity of cancer cells expressing GOF mutant p53. We
used three shp53 clones and two shGFP clones to rule out clonal variations, and got similar
results. Taken together, these studies demonstrate that p53 mutants contribute to multiple GOF
phenotypes in a wide range of cancer cell lines with endogenous p53 mutations.
Thus, different cell lines with different endogenous mutant p53 tested show similar loss
of GOF activities in reducing the level of mutant p53 (Figures 3-5), suggesting the generality of
the conclusion that mutant p53 levels determine GOF phenotypes.
Reducing NF-κB2 levels in cancer cells with mutant p53 by RNAi lowers GOF
activity of mutant p53-expressing cells. We proposed earlier that mutant p53-induced GOF
activity (such as chemoresistance) in cancer cells may be due to induction of NF-κB2 by mutant
p53 (110). If that is the case then reducing the level of NF-κB2 in cancer cell lines with mutant
p53 should reduce chemoresistance.

Since reduction of mutant p53 levels reduces GOF

activities in a number of cancer cell lines, we tested the idea whether a similar effect can be seen
by reducing the level of NF-κB2.

RNAi directed against NF-κB2 using MDA-MB-435

melanoma cells harboring a p53-G266E substitution (one of the cell lines tested in p53 knock
down experiments above) was used for this. The data presented in Figure 6A and 6C show that
RNAi directed against NF-κB2 reduces the level of expression of the corresponding gene, and
reduces resistance to the chemotherapeutic drug etoposide substantially versus DMSO.
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Figure 5. p53 knock down in cancer cell lines with naturally occurring p53 mutations
causes a decrease in rate of motility and tumor growth. A. The indicated cell lines were
cultured to confluence, a scratch made in the monolayer, and the distance measured as described
in Methods. p>0.001 for both. Two mutant p53 knocked down clones (confirmed by Western
blot, as indicated) were used for each cell line with the average migration between the clones
shown. Error bars represent standard deviation from the mean migration rate. B. Mutant p53
levels were knocked down in the lung cancer cell line H1048 (p53-R273C) by lentivirus
expressing p53 shRNA or GFP shRNA (used as our control cell line) as indicated and its
tumorigenic ability measured after subcutaneous injection into nude mice. For all injections,
1x107 cells/250µl media were used. Mice were injected subcutaneously and tumors allowed to
grow to a maximum size of 1cm, measuring periodically as described before (17, 18). Three
different clones of H1048 cells with mutant p53 levels knocked down by shRNA were used in
comparison to two GFP shRNA control cell lines to eliminate clonal variations. Average tumor
size was calculated by taking the average of the width and length of each tumor, then taking the
average of all tumors from the particular cell line.
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Furthermore, cell motility –another GOF p53 phenotype – is significantly inhibited by NF-κB2
RNAi (Figure 6B). p53 RNAi also inhibited cell migration (not shown), consistent with results
with NF-κB2 RNAi. Thus, NF-κB2 at least partially regulates two mutant p53 GOF phenotypes
in these cells, suggesting the possibility that mutant p53 may induce its GOF activity via NF-κB2
up-regulation, an observation we reached by expressing mutant p53 in H1299 lung carcinoma
cell lines that are normally p53 null (196). Figures 6D and 6E show reduced resistance to the
chemotherapeutic drug paclitaxel after treatment with RNAi against NF-κB2 in H1299 cells
expressing either an empty vector (HC5) or the p53 mutant R273H, and Western analysis
showing decreased NF-κB2 protein expression.

Our data obtained by p53 knock down

experiments, using cancer cell lines with naturally occurring mutant p53, and ectopic expression
of mutant p53, in p53 null lung cancer cells, are similar, and interchangeable in this respect.
Having determined that, we decided to determine the mechanism of up-regulation of NF-κB2 by
mutant p53 using H1299 cell systems where mutant p53 was expressed.
Promoter deletion analysis by transient transcription assays does not indicate a
mutant p53 response element. To test whether we could detect a mutant p53 response element
on the NF-κB2 promoter, we generated a number of deletion mutants of the NF-κB2 promoter
(110) by PCR and subcloned them into the pGL3-basic plasmid vector (Promega). We tested
their promoter function by transient transfection in H1299 p53-null lung carcinoma cells as
described (110). After harvesting the cells at 48 h post-transfection, we prepared extracts and
determined the luciferase activity as described (110). Data presented in Figure 7 show that none
of the deletion mutants eliminated the transactivation capacity of mutant p53–R273H. Some of
the deletions resulted in higher transactivation by mutant p53 suggesting that some sequences of
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Figure 6. Reduction of NF-κB2 causes reduction of drug sensitivity, growth rate and rate
of and motility. A. Chemoresistance of MDA-MB-435 cells depends on the NF-κB2 level.
The indicated cells were transfected with control or NF-κB2-specific siRNA, treated with
etoposide, and colony formation determined as described in Materials and methods (upper
panels). Percent survival is shown in the figure with error bars representing standard deviation
from the average number of colonies from triplicate samples. B. Motility of MDA-MB-435
cells depends on the NF-κB2 level. MDA-MB-435 cells were transfected as above. 48h later,
standard Transwell migration assays were carried out, and migrating cells stained and counted as
described (197). Bar = +/- 1 SD from the mean of 18 samples. C. NF-κB2 and Erk2 levels were
determined by immunoblotting for MDA-MB-435 cells used in A and B. D. H1299 cells
expressing an empty vector (HC5) or p53-R273H were treated with control (si-scrambled) or
RNAi against NF-κB2, treated with paclitaxel, and colony formation determined as described in
Materials and methods. E. Western analysis of NF-κB2 knock down by siRNA in H1299 cells
expressing an empty vector or p53-R273H.
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Figure 7. Promoter deletion analysis by transient transcription analysis does not indicate a
mutant p53 response element. A number of NF-κB2 (110) promoter deletion mutants were
generated by PCR, and their promoter activity was measured by transient transcriptional analysis
using H1299 p53-null lung cancer cell lines transfected with empty vector as control, or p53R273H (left panel) or p53-D281G (right panel). Forty-eight hours after transfection, cells were
harvested and luciferase assays were performed using equal amounts of protein. The figure
shows a representative example of multiple experiments. Relative fold of activation in luciferase
activity has been plotted compared to that obtained by vector alone. Error bars indicate
deviations in luciferase readings relative to vector transfected cells. All experiments were done
in triplicate.
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the promoter may act negatively on transactivation; the reason for that needs further
investigation. We also tested another mutant, p53-D281G, with the full-length and the largest
promoter deletion mutant. Both were transactivated, showing that this sequence independence
has generality as far as mutant p53 is concerned. Thus, transient transcriptional analysis failed to
provide evidence for a mutant p53 response element on the NF-κB2 promoter. These data are in
agreement with those published by us earlier (198) where EGFR promoter deletion did not result
in identification of a mutant p53 response element either. Therefore, it is possible that the gene
specificity is attained at the chromatin level.
ChIP analysis indicates mutant p53 induced histone acetylation on the NF-κB2
promoter. Because mutant p53 can demonstrate GOF activity in different cells, and presumably
one of its important targets is NF-κB2, we used H1299 cells in which mutant p53-R273H is
expressed as a model to explore the mechanism of up-regulation. We wanted to test whether
mutant p53 alters the chromatin structure on the endogenous NF-κB2 promoter in H1299 cells.
Therefore, we performed ChIP assays using H1299 cells stably transfected with empty vector
alone (HC5) or H1299 cells expressing mutant p53-R273H. The data shown in Figure 8A
demonstrate that mutant p53 induces formation of acetylated histone H4 (but not acetylated
histone H3) on the NF-κB2 promoter in H1299 cells expressing mutant p53–R273H, suggesting
that the up-regulation of NF-κB2 expression by mutant p53 seen in these cells may occur via a
transactivation role of mutant p53 executed at the NF-κB2 promoter through chromatin
modification.
Mutant p53 induces binding of CBP and STAT2 on the NF-κB2 promoter. To
extend our studies, we used ChIP analysis to determine whether there is preferential
enhancement of interaction of one or more transcription factor(s) on the NF-κB2 promoter in

29

H1299 cells stably transfected with vector alone (HC5) or expressing mutant p53-R273H. The
transcription factors CREB, NF-κB p65, STAT2, CBP, c-Rel, and p53 were chosen for ChIP
analysis based on transcription factor binding sites located on the NF-κB2 promoter as well as
known interactions.

The data presented in Figure 8B show that STAT2 nucleation, as

determined by ChIP assays, is significantly higher in mutant p53 expressing cells. Thus, our
results demonstrate that mutant p53 induces STAT2 interaction on the NF-κB2 promoter, and
suggests a STAT2-mutant p53 mechanism. Similarly, when tested by ChIP analysis, CBP, a
histone acetyltransferase, is nucleated more on the NF-κB2 promoter in the presence of mutant
p53 (Figure 8C).

This suggests that CBP nucleation enhances histone acetylation on the

promoter.
Figure 8 also shows no enhanced nucleation of mutant p53 on the NF-κB2 promoter as
we did not observe any additional promoter fragments immunoprecipitated by p53 antibody DO1
or a p53 antibody recognizing the total protein (Figures 8C and 8D). This suggests that under the
conditions of our assay, including cross-linking, we were unable to detect mutant p53 directly on
the promoter. It is possible that by changing conditions we may be able to detect mutant p53 on
the promoter if it is nucleated via protein-protein interactions.

Chapter Summary.
Since a previous report suggested part of mutant p53’s chemoresistance was due in part
to up-regulation of NF-κB2, this chapter investigated the role NF-κB2 plays in mutant p53
mediated gain of function. We report that p53-mediated NF-κB2 up-regulation significantly
contributes to the aggressive oncogenic behavior of cancer cells. Lowering the level of mutant
p53 in a number of cancer cell lines resulted in a loss of GOF phenotypes directly implicating
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Figure 8. ChIP analysis indicates acetylation of histones on the NF-κB2 promoter. ChIP
analysis was performed on H1299 cells stably transfected with vector (HC5) or mutant p53R273H (R273H) to test whether histones are preferentially acetylated on the NF-κB2 promoter,
and if different transcription factors and mutant p53 are nucleated on the promoter. A. ChIP
performed with antibodies directed against acetylated histone H3 (acetylated at K9 and K14) and
H4 (acetylated at K16). B. ChIP performed with antibodies directed against CREB, NF-κB p65,
and STAT. C. ChIP performed with antibodies directed against CBP, cRel and p53 DO1. D.
ChIP performed with an antibody against the total p53 protein
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p53 mutants in the process. RNAi against NF-κB2 in naturally occurring cancer cell lines also
lowered GOF activities. In H1299 cells expressing mutant p53, chromatin immunoprecipitation
(ChIP) assays indicated that mutant p53 induces histone acetylation at specific sites on the
regulatory regions of its target genes. ChIP assays using antibodies against transcription factors
putatively capable of interacting with the NF-κB2 promoter show increased interaction of CBP
and STAT2 in the presence of mutant p53. Thus, we propose that in H1299 cells, mutant p53
elevates expression of genes capable of enhancing cell proliferation, motility, and tumorigenicity
by inducing acetylation of histones via recruitment of CBP and STAT2 on the promoters causing
CBP-mediated histone acetylation.
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Chapter 2
DETERMINE HOW MUTANT P53 UTILIZES RECEPTOR TYROSINE KINASE
AXL TO ACCOMPLISH ITS GAIN-OF-FUNCTION ACTIVITY
The work presented in this chapter has been published in the Genes and Cancer research journal (Genes
Cancer. 2012 Jul;3(7-8):491-502.). Microarray data was analyzed by Brad Windle, Western analysis of H1299 cells
expressing different p53 mutants was performed by Shilpa Singh, the H1793 growth assay was performed by Becky
Frum, and the motility assays were performed by Andrew Yeudall.

Introduction.
We and others have identified several genes important for their involvement in growth
and oncogenesis that are regulated at the level of expression by GOF mutant p53 (110, 135, 178,
199-202). Receptor tyrosine kinases (RTKs) play an important role in growth and differentiation
of normal cells, and represent a major class of protooncogenes, involved in the progression and
metastasis of cancer (203). Axl/Mer/Sky represents a comparatively recent class of the RTK
family that induces extracellular signals inside cells (204). Axl is a RTK with transforming
activity (205, 206), and may be used as a target for therapy (207).
The antiapoptotic, cell adhesion, and chemotactic activities of Axl have been ascribed to
an increased expression of Axl and its increased interaction with Gas6 (208). The invasiveness
and metastasis in various cancer cell types is associated with an elevated level of Axl expression,
which is also correlated with poor prognosis of patients with various cancers such as: myeloid
leukemia (205, 209), metastatic lung cancer (210, 211), breast cancer (212), and gastric cancer
(213). Use of RNAi techniques and dominant-negative receptor mutants of Axl have resulted in
growth suppression of cancer cells in a xenograft model (214, 215).
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Here, we show that the receptor protein tyrosine kinase Axl is up-regulated by p53
mutants in H1299 lung cancer cells expressing mutants p53-R175H, -R273H, and –D281G.
Knock-down of Axl by Axl-specific RNAi caused reduction of GOF activities in lung cancer
cells expressing endogenous mutant p53 suggesting that mutant p53 may induce Axl as one of
the target genes to execute its GOF activities.

Materials and Methods.
Cell lines. Four human lung cancer cell lines: H1299 (p53-null, NSCLC), H1048
(p53-R273C, SCLC), H1437 (p53-R267P, NSCLC), ABC-1 (p53-P278S, Adenocarcinoma), and
H1793 (p53-R273H, NSCLC) were used in these studies. H1299, H1048, and H1437 were
grown in RPMI media supplemented with 10% fetal bovine serum while H1793 was grown in
DMEM supplemented with 5% fetal bovine serum.
Generation of H1299 cells expressing GOF p53 mutants.

To determine whether

expression of mutant p53 leads to GOF phenotypes in human cells, we have used the H1299
(p53-null) lung cancer cell line and generated cells expressing p53 mutants -R175H, -R273H and
-D281G (216).

These GOF p53 mutants are commonly found in human cancer

[http://www.iarc.fr/p53/Index.html].
Generation of mutant p53 knock down cell lines. The independent cell lines H1048,
ABC-1, and H1437 were used to make stable p53 knock down cell lines. They were generated
by using lentivirus expressing short hairpin RNA (shRNA) against p53 utilizing lentivirus
systems (Open Biosystems) following the manufacturer’s protocol. Clones were isolated using
puromycin selection at 1 µg/ml.
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Expression analysis. Microarray analysis was carried out as described previously (110,
134) after isolating RNA from H1299 cells expressing p53 mutants or stably transfected with
vector alone. We analyzed expression of different genes using Affymetrix U95Av2 arrays as
described earlier (110, 134). QPCR analysis of RNA levels were also done as described before
(110, 134).
Tumor RNA analysis and p53 sequencing. Tumor RNAs were provided by the Tissue
and Data Acquisition and Anaylsis Core repository under an Institutional Review Board
approved protocol; cDNAs were prepared using the Superscript III cDNA synthesis kit
(Invitrogen) and QPCR performed using primers specific for Axl (F: 5’-TGT TTG GTG TTT
CTG GGA CA-3’ and R: 5’-TCG CAG GAG AAA GAG GAT GT-3’).

The degree of

expression was quantitated using a relative standard curve and normalized to GAPDH (F: 5’GTC AAC GGA TTT GGT CGT ATT-3’ and R: 5’-GAT CTC GCT CCT GGA AGA TGG-3’)
corresponding to the cDNA batch. The p53 gene is sequenced following the method described
by Sjogren et al. (217). Whenever a mutation is found, a new PCR reaction is performed and
fragment re-sequenced to verify sequence information obtained previously. The AXL levels in
the two populations of tumors, one with WT p53 and one with mutant p53, were compared and
found to be different with a statistically significant difference based on the student t test.
siRNA transfection.

Lung cancer cells were transfected with Lipofectamine 2000

(Invitrogen) two times (once every 24 hours) with RNAi directed against a specific or nonspecific gene (luciferase) following the manufacture’s protocol. Sequences used were: Control
(C): 5’- CAU GUC AUG UGU CAC AUC ACT T -3’ and 5’-GAG AUG UGA CAC AUG ACA
UGT T -3’ and Axl siRNA, was purchased from Santa Cruz Biotechnology. Forty eight hours
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after transfection, cells were trypsinized, counted, plated and growth or migration assays were
carried out as described below.
Growth assay. Growth assays were carried out as described by us earlier with slight
modifications (110, 135). Cells were plated at 50,000 cells/6cm dish in triplicate for five time
points and harvested after incubation with trypsin and counted using a Coulter Counter
(Beckman). Each set of triplicate plates was counted three times, giving a total of nine counts
per siRNA treatment per day. To determine the number of cell doublings, the ratio of Axl and
control (Scram) siRNA treated cells was calculated to be the number of cells counted on day two
divided by day one, and so on for the five time points. The ratios throughout the assay were
averaged and plotted, and the standard deviation was calculated to be the difference in ratios
from the triplicate counts per time point. All experiments were done in triplicate, and repeated
multiple times.

The cells lines were analyzed for growth rate using replicates based on

exponential growth. The statistical difference between growth rates was determined by the
student t test.
Axl promoter cloning and transient promoter assays. Axl promoter and its deletion
mutants were cloned in pGL3-basic vector using sequence information available in NCBI. The
primers used to generate the Axl promoter deletions were: 0-959: 5’-CCG GGG TAC CCG CAG
GCA GCA GAT CTG CAA TAA C-3’ and 0-200: 5’-CCG GTT ACC GGG AGT GAG GGA
AGG AGG CAG GGG TGC TGA-3’. Transient transfection was performed with 200ng of
promoter and 1ug of expression plasmid using Lipofectamine 2000 (Invitrogen) following the
manufacturer’s instructions.

Luciferase analysis was carried out using the luciferase assay

system (E1500) and instructions from Promega. Both transfection and luciferase assay were as
described previously in triplicate (218).
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Chromatin immunoprecipitation. Chromatin immunoprecipitations were performed as
described (134).

To crosslink protein and DNA, cell cultures were incubated in 2%

formaldehyde for 10min at 37°C and then 200mM glycine was added for a further 10min. Cells
were washed in cold phosphate buffered saline (PBS), scraped and centrifuged. Pellets were
resuspended in lysis buffer containing 1% protease inhibitors and then sheared by six passages
through a 27.5 gauge needle followed by 25min of sonication on ice such that the chromatin is
fragmented to 500–2000bp in length. Following centrifugation, the protein content of the
supernatants was determined and equal amounts used for immunoprecipitation overnight at 4ºC
with gentle tilting with protein-specific antibodies or IgG as a control. Immune complexes were
captured using Protein A-agarose, then washed sequentially in RIPA buffer (150mM NaCl,
50mM Tris pH8, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40), high salt buffer (500mM
NaCl, 50mM Tris pH8, 0.1% SDS, 1% NP-40), twice in LiCl buffer (250mM LiCl, 50mM Tris
pH8, 0.5% sodium deoxycholate, 1% NP-40) then twice in TE buffer. Protein was eluted from
beads in fresh elution buffer (20% SDS, 10mM DTT, 100mM NaHCO3), crosslinking reversed
overnight at 65ºC in the presence of NaCl, and then samples were ethanol-precipitated.
Following centrifugation, pellets were resuspended in TE buffer and incubated sequentially with
10mg/ml RNase A (30min) and 20mg/ml proteinase K (1h). Samples were phenol-extracted,
ethanol-precipitated, and the pellets washed in 70% ethanol, dried and resuspended in sterile
water. Acetyl histone H3 (17-615), acetyl histone H4 K8 (07-328), and normal rabbit IgG were
from Millipore. p300 (sc-585), CREB (sc-186), E2F1 (sc-22820), p53 DO1 (sc-126), and p53
FL393 (sc-6243) were obtained from Santa Cruz. PCR primers used to analyze ChIP samples
were: Axl (5kb) F: 5’-CCT TGA CTG AGG CTT TAC CA-3’ and R: 5’-TTT TCA AAG TGC
ACC GAC AT-3’; and Axl F: 5’-GAT GCA GCA GTT CCC AAA AT-3’ and R: 5’-TAT CAT
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CCC TTC TCC ATC GC-3’. The Axl promoter scanning primers are: Axl 2200-2000bp are the
same primers indicated above, 1-400bp F: 5’-CCC CGT CTC TAC CAA AAA TA-3’ and R: 5’GGC CCT TCA CCG TTG T-3’; 401-800bp F: 5’-GAA GGG GCA GGT AGA AGA GA-3’
and R: 5’-AGC CCT GAT CAT TCC ACT G-3’; 801-1200bp F: 5’-AGC GAT CCT CCC ACC
TT-3’ and R: 5’-ATC TTC AGA CAC GCC AAA AC-3’; 1201-1600bp F: 5’-TCT GCG TGT
CTC TGC TTG TC-3’ and R: 5’-TCT GGG CTC TGT GTC TGG TA-3’; and 1601-2000bp F:
5’-GGT CCC CTT CCC CCT CCT CA-3’ and R: 5’-CCC AGC AGC CGC CTT CTC A-3’.
Axl (5kb) corresponds to a sequence 5 kb upstream of the Axl gene without any regulatory
sequences in it. This was used to normalize the QPCR values. The percent p53 binding was
calculated by determining the fold activation of the Axl promoter by mutant p53 (versus control)
for each region of the promoter. Five sets of ChIP experiments were averaged and the percent
binding was calculated by setting the Axl ChIP primers (2200-2000bp) as equal to 100%. The
standard deviation was calculated between the five sets of experiments and plotted.
Western blotting. Immunoblottings were carried out as described (110). Axl levels
were detected using an antibody from Abnova (H00000558-M01). Erk2 (sc-154) and β-tubulin
(sc-5274) levels were detected by antibodies from Santa Cruz. p53 was detected using the p53
antibody PAb 1801 (93). Westerns blots were developed by the ECL method (GE Healthcare;
Piscataway, NJ).
Migration assays. Cell migration was carried out using wound-healing (scratch) assays,
as previously described (219). Briefly, cells were trypsinized, plated in quadruplicate in 12-well
cell culture plates and incubated at 37°C until cells were completely confluent. At this time, a
sterile pipette tip was used to scratch across the surface of the plate, removing the complete layer
of cells within the scratch area. Following cell removal, each well was washed once with PBS
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and then replaced with growth medium. Immediately following, the width of the scratch was
measured at six specific points under a 5x objective using a light microscope and AxioVision
software (Carl Zeiss Microimaging, Thornwood, NY). Cells were incubated at 37°C from 20-60h
depending on the cell line under study, at which time the scratch width was measured at the same
position as at time 0.

Experimental Results.
The transactivation-deficient mutant p53-D281G (L22Q/W23S) is effective in
up-regulating many mutant p53 target genes.

We focused our attention on potential

mechanisms of GOF mutant p53 by studying the role for p53’s transactivation domain in gene
regulation.

We determined whether the triple amino acid substitution mutant p53-D281G

(L22Q/W23S) has retained the ability to up-regulate expression of mutant p53 target genes
identified by our expression analysis (110). We compared gene expression profiles of three
H1299 cell lines stably transfected with vector alone (HC5), stably expressing p53 mutant –
D281G, and the transactivation domain mutant -D281G (L22Q/W23S) using Affymetrix
GeneChip arrays. The data shown in Table 1 shows a list of examples genes induced by p53
D281G and not affected by the 22Q, 23S mutations (p-value = 3x10-24). This indicates that a
substantial part of the mutant p53 gene expression signature is independent of the transactivation
domain at codons 22 and 23.
Interaction between mutant p53 and p63 has been demonstrated and shown to be
independent of the transactivation domain mutants (220). The mutant p53 induced genes we
identified that are not dependent on the transactivation domain might involve a mutant p53-p63
interaction. We analyzed mutant p53 induced genes for over-representation of genes that contain
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putative p63 binding sites. The Axl gene was selected for further study based on the presence of
a p63 binding site, it’s known role in oncogenesis (205, 211, 214, 221, 222), and it’s potential
role in mutant p53 GOF activities. We first verified the microarray data by performing RTQPCR quantitation of the Axl mRNA, confirming induction by mutant p53. Data presented in
Figure 9A show presence of more Axl RNA in the H1299 cells expressing mutant p53 compared
to vector transfected cells (compare lanes HC5 with R175H, R273H, D281G and D281G
(L22Q/W23S)).

We also tested the Axl expression at the protein level by performing

immunoblot analysis as described in Materials and Methods. Protein expression analysis shown
in Figure 9B demonstrates that cell lines expressing mutant p53 express higher levels of Axl
protein compared to the vector transfected cells. This induction of Axl protein expression by
mutant p53 remains when the transactivation domain mutations at codons 22 and 23 are present,
confirming our RNA expression analysis. Similar data was also observed when we compared
Axl levels in H1299 cells expressing p53-R273H and -R273H with additional mutations at
codons 22 and 23 (Figures 9C and 9D).
We investigated if the converse was true, that reduced expression of endogenous mutant
p53 would result in reduced expression of Axl. We studied the Axl RNA level in two lung
cancer cell lines with endogenous mutant p53, H1437 (p53-R267P) and H1048 (p53-R273C),
after knock-down of the mutant p53 levels in these lines by generating stable cell clones using
lentivirus vectors expressing p53 shRNA with comparison to control cells expressing green
fluorescence protein (GFP) shRNA. Data depicted in Figure 10A shows that reduction of mutant
p53 levels is accompanied by a reduction of Axl levels suggesting, along with the mutant p53
induction studies, that mutant p53 regulates Axl expression.
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Figure 9. H1299 cells expressing gain of function mutant p53 up-regulate protein receptor
tyrosine kinase Axl. A and C. Reverse transcriptase (RT) QPCR analysis of Axl levels in
H1299 cells stably transfected with vector or mutant p53 expression plasmids. QPCR was
performed for GAPDH and was used to normalize with Axl values. B and D. Western blot
analysis of Axl levels in H1299 cells stably transfected with vector or mutant p53 expression
plasmids. Data shows mutant p53 induced Axl expression both at RNA and protein levels in
H1299 cells, and this induction is not disturbed by mutations at amino acids 22 and 23. Error
bars showing standard deviations are indicated.
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Lung tumors cells expressing mutant p53 show higher Axl levels. Since we observed
that mutant p53 up-regulates Axl expression in lung cancer cell lines studied, we investigated
whether this is also valid in human lung tumors expressing mutant p53. Figure 10B depicts the
Axl level of different human lung tumors collected in Virginia Commonwealth University cancer
tissue repository. On average, there was significantly more Axl expression in samples with
mutant p53 versus samples with WT p53 (average 5.63-fold, p-value 0.013) corroborating our
cell culture data that mutant p53 upregulates Axl expression.
Axl up-regulation mediates GOF activities of mutant p53.

Axl is known to be

involved in promoting growth and movement of cells (208, 210, 214, 215, 222-224). Therefore,
we tested whether mutant p53-induced enhancement of growth and motility has any relationship
with the fact that mutant p53 up-regulates expression of Axl. We used the lung cancer cell line
H1048 expressing a mutant p53 (-R273C) for testing its growth rate and motility as described in
Materials and Methods. To test whether the level of Axl affects the properties affected by GOF
of mutant p53 expression, we transfected this cell line with siRNA against Axl (or control
scrambled siRNA), and performed the growth and motility assays.

Figure 11A shows a

representative example of the growth effect showing a reduction of growth rate (shown as cell
doubling/day) when the Axl level is reduced (p-value 0.0065). This suggests a correlation
between mutant p53-mediated up-regulation of Axl level and the growth rate enhancement
induced by mutant p53. We also tested the relationship between cell motility rate and Axl level
in these cells. As shown in Figure 11B there is a significant reduction in cell mobility rate as
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Figure 10. Lung tumor cells expressing p53 mutations show higher Axl levels. A. RTQPCR of Axl mRNA levels in lung cancer cell lines H1437 and H1048. Lung cancer cell lines
H1048 and H1437 were infected with control shRNA or p53 shRNA lentivirus to generate
mutant p53 knock down cell lines. Western blot analysis was performed on isolated clones to
identify p53 knock down clones. Erk2 was used as a loading control. These clones were further
analyzed for Axl mRNA expression by QPCR using primers specific for the Axl gene and
normalized by GAPDH. The data indicates lowering of mutant p53 levels lowers Axl levels. B.
RT-QPCR of Axl levels in lung tumors. cDNA was prepared from human lung tumor RNAs
(labeled VLU to protect patient identity) and a normal tissue sample (labeled 2N). The degree of
expression was quantitated using a relative standard curve and normalized to GAPDH
corresponding to the cDNA batch.
44

measured by scratch assays when the Axl level is reduced by the Axl siRNA even though the
mutant p53 level remains unchanged. Similar data have been obtained from H1793 cell as well
(Figures 11C, 11D). Thus, mutant p53 may induce some of its GOF activities via induction of
Axl.
Mutant p53 up-regulates the Axl promoter.

We have evidence that mutant p53

expressing cells have higher Axl levels both at RNA and protein levels (see above); therefore, we
determined whether the upstream sequences of the human Axl gene can act as a faithful
regulatory promoter in a transient promoter assay. We have cloned a 2000 bp long fragment
encompassing the upstream sequences of the Axl into the pGL3 basic luciferase reporter vector
(Promega), and tested its promoter activity by transient transfection analysis. We transfected
p53-null human lung cancer H1299 cells with Axl-pGL3 basic in the presence and absence of
different p53 expression plasmids and after 48 hours performed luciferase assays as described
(110, 225). The data shown in Figure 4 indicate that mutant p53 up-regulates the Axl upstream
sequences as expected. The Axl promoter sequence contains a putative p53/p63 binding site on
the Axl upstream sequences raising the possibility of its involvement in mutant p53-mediated
transactivation since some studies of GOF functions have implicated the p63-mutant p53
interactions (179, 180, 226, 227). Data shown in Figure 12 (and Figure 13, see below) also show
that p63 (full length p63γ) and WT p53 could transactivate the Axl promoter depending on the
presence of the p53/563 binding site.
Mutant p53 up-regulates the Axl promoter in H1299 cells independent of the p63
binding site. We generated two Axl promoter deletion mutants with and without the p63binding site and tested whether transactivation by mutant p53 requires the p63-binding site. The
data presented in Figure 13 shows that p63-mediated transactivation is lost by a deletion of the
45

Figure 11. Axl up-regulation by mutant p53 has physiological significance. A and C.
Growth rate of H1048 and H1793 lung cancer cells depends on the Axl level. H1048 and H1793
cells were transfected with control or Axl-specific siRNA, plated in equal numbers, and
harvested each day for five days to determine the rate of doubling. In parallel, p53, Axl and Erk2
levels were determined by immunoblotting (right panel). B and D. Motility of H1048 and
H1793 cells depends on the Axl level. H1048 and H1793 cells were transfected as above. 48h
later, standard scratch assays were carried out as described in Materials and Methods, and
migrating cells stained and counted. Bar = +/- 1 SD.
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Figure 12. Mutant p53 up-regulates the Axl promoter in H1299 cells. H1299 cells were
transfected with 200ng of pGL3-basic vector containing the Axl promoter upstream of the
luciferase reporter gene, and 1ug of the indicated p53 expression plasmid. Cells lysates were
prepared 48hr after transfection, and luciferase activity was determined. Data is shown as fold
activation over control. Experiments were done in triplicate.
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Figure 13. Mutant p53 up-regulates the Axl promoter in H1299 cells independent of the
p63 site. Two deletion mutants of the Axl promoter were constructed and tested for promoter
activity in H1299 cells in the presence and absence of mutant p53 and p63 to determine if the
putative p63-binding site is required for mutant p53-mediated transactivation. The data indicates
that mutant p53 does not require the p63 binding site to transactivate the Axl promoter. H1299
cells were also co-transfected with pGL3 basic or the larger Axl deletion mutant and empty
vector or mutant p53 to ensure the transactivation capabilty is not lost. Data is shown as fold
activation over control. Experiments were performed in triplicate.
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p63-binding site; however, mutant p53-induced transactivation remained undisturbed even in the
absence of the p63-binding site while the negative control (pGL3-basic alone) did not get
activated at all. This suggests that GOF mutant p53 transactivates the Axl promoter independent
of the p63 binding sites in transient transfection assays.
Mutant p53 induces acetylation of histones on the Axl promoter. We used H1299
cells expressing mutant p53-R273H as a model to study the mechanism of up-regulation of Axl
expression by mutant p53. We performed ChIP assays using H1299 cells stably transfected with
empty vector alone or H1299 cells expressing mutant p53-R273H using an antibody directed
against acetylated histone to assay for the extent of histone modification as a measure of
transcriptional activity at this gene. The data shown in Figure 14A and 14B demonstrate that
mutant p53 induces enhanced formation of acetylated histone H3 and H4 on the Axl promoter in
H1299 cells expressing mutant p53-R273H, suggesting that the up-regulation of Axl expression
by mutant p53 seen in these cells may occur via a transactivation role of mutant p53 through
chromatin modification at the Axl promoter location.
Knock-down of mutant p53 reduces histone acetylation on the Axl promoter. Since
the overexpression of mutant p53 induces the acetylation of histones on the Axl promoter, we
wanted to see if the reduction of mutant p53 would produce the opposite effect. We used two
lung cancer cell lines, ABC-1 (p53-P278S) and H1048 (p53-R273C) after knock-down of their
endogenous mutant p53 using a shRNA lentivirus directed against p53 or control GFP. The data
shown in Figures 14C and 14D show a decrease of histone acetylation upon mutant p53
reduction compared to GFP control in both ABC-1 (Figure 14C) and H1048 (Figure 14D) cell
lines. This further supports the idea that mutant p53 up-regulates Axl expression via chromatin
modification.
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Figure 14. ChIP assay demonstrates increased acetylation of histones on the Axl promoter.
ChIP analysis was performed on H1299 cells stably transfected with vector (HC5) or mutant
p53-R273H (R273H) to test whether histones are preferentially acetylated on the Axl promoter.
A. ChIP performed with an antibody directed against acetylated histone H3 (acetylated at K9 and
K14). B. ChIP performed with an antibody directed against acetylated histone H4 (acetylated at
K8). C and D. ChIP performed on ABC-1 and H1048 p53 knock-down cell lines using an
antibody directed against acetylated histone H3 (acetylated at K9 and K14) shows a reduction in
histone acetylation on the Axl promoter. Experiments were done in triplicate.

50

Nucleation of mutant p53 on the Axl promoter. Next we examined if we could locate
mutant p53 on the Axl promoter sequences using the ChIP and H1299 cell systems described
above (Figure 14). Here, chromatins were immunoprecipitated using p53 antibodies D01 and
FL-393 (Santa Cruz), or corresponding antibody controls, as described in Materials and
Methods. Immunoprecipitated DNA was quantified by QPCR, and data is shown in Figure 15A.
It is clear that mutant p53 got localized on the sequences upstream to the Axl gene either directly
or indirectly binding to DNA. To locate the site or sites of mutant p53 binding to the Axl
promoter, the full length promoter was divided into five fragments and primers were designed.
Fold activation by mutant p53 on the Axl promoter was determined and the percent of p53
binding was calculated (Figure 15B). The data shown indicate major mutant p53 interaction
distal to ATG.
Transcription factor binding is enhanced by mutant p53 on the Axl promoter. Next,
we wanted to check whether we could determine the transcription factor(s) that bind more
efficiently on the Axl promoter in the presence of mutant p53 (Figure 16). For that purpose we
performed ChIP assays using antibodies against transcription factors, p300, E2F1, and CREB,
which putatively may interact with the Axl promoter. ChIP assay data carried out using vector
transfected and mutant p53 (-R273H) expressing H1299 cells and corresponding antibodies
against these transcription factors show that binding all transcription factors are increased: p300
2.5-fold, E2F-1 4.3-fold and CREB 8-fold. Increased binding of transcription factors is likely to
contribute to the induced Axl expression mediated by mutant p53.
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Figure 15. ChIP data showing p53-R273H binding in H1299 cells expressing this mutant
to the Axl promoter region. A. ChIP was performed on H1299 cells stably transfected with
vector (HC5) or mutant p53-R273H (R273H) to test whether mutant p53 is nucleated on the
promoter. B. Primers were designed to amplify the full length Axl promoter in five regions:
2000-1601bp, 1201-1600bp, 801-1200bp, 401-800bp, and 1-400bp. QPCR was performed for
each of these fragments on H1299 cells expressing either an empty vector (HC5) and p53-R273H
that were used for ChIP with antibodies against p53 (D01 and FL393) or IgG as a control.
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Figure 16. ChIP assay shows the mutant p53 mediated increase in transcription factor
binding on the Axl promoter. ChIP analysis was performed on H1299 cells stably transfected
with vector (HC5) or mutant p53-R273H (R273H) to test whether transcription factors are
preferentially binding to the Axl promoter. ChIP was performed with antibodies directed against
CREB, E2F1, and p300. Experiments were done in triplicate.
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Chapter Summary.
Microarray data of H1299 lung adenocarcinoma cells expressing different p53 mutants
showed up-regulation of genes that may affect growth and oncogenesis. We have investigated
the receptor protein tyrosine kinase Axl, which is up-regulated by p53 mutants at both RNA and
protein levels in H1299 lung cancer cells expressing mutants p53-R175H, -R273H, and –D281G.
Knock-down of endogenous mutant p53 levels in human lung cancer cells H1048 (p53-R273C)
and H1437 (p53-R267P) led to reduction of the level of Axl as well. This effect on Axl
expression is refractory to the mutations at positions 22 and 23 of p53 suggesting that p53’s
transactivation domain may not play a critical role in the up-regulation of Axl gene expression.
Chromatin immunoprecipitation (ChIP) assays carried out with acetylated histone antibodies
demonstrated induced histone acetylation on the Axl promoter region by mutant p53. Direct
mutant p53 nucleation on the Axl promoter was demonstrated by ChIP assays using antibodies
against p53. The Axl promoter has a p53/p63 binding site, which however, is not required for
mutant p53-mediated transactivation. Knock-down of Axl by Axl-specific RNAi caused
reduction of gain of function (GOF) activities, reducing cell growth rate and motility rate in lung
cancer cells expressing mutant p53. This indicates that for lung cancer cell lines with mutant
p53, GOF activities are mediated in-part through Axl.
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Chapter 3
DETERMINE HOW UP-REGULATION OF EPIDERMAL GROWTH FACTOR
RECEPTOR (EGFR) AFFECTS ADDICTION OF LUNG CANCER CELLS TO GAINOF-FUNCTION MUTANT P53
The manuscript for the work presented in this chapter is currently under preparation. Growth assays and
immunoprecipitations were performed by Isabella Pearsall, migration assays were performed by Andrew Yeudall,
Western blot analysis on the different human lung cancer cell lines was performed by Shilpa Singh.

Introduction.
In earlier work, we have shown that GOF p53 transactivates the human EGFR promoter
in transient transfection assays in the absence of specific DNA binding by p53 (198, 228).
EGFR is involved in cell proliferation and motility (229) and its over-expression has been found
to be implicated in various cancers including lung cancer (230). The mechanism through which
GOF p53 up-regulates gene expression is not yet clear.
In this project, we show that lung cancer cells expressing GOF p53 are addicted to mutant
p53; knock-down of p53 in lung cancer cells causes lowering of tumorigenicity and other GOF
properties. We demonstrate that mutant p53 up-regulates epidermal growth factor receptor
(EGFR) expression and activates the EGFR pathway. Knock-down of p53 lowers EGFR
overexpression; however, the addiction to GOF p53 can be compensated by overexpressing
EGFR suggesting that EGFR is in the GOF p53 pathway and plays a critical role in the addiction
of lung cancer cells to GOF p53. Using chromatin immunoprecipitation (ChIP) assays we show
that GOF p53 interacts with the EGFR promoter and increases H3 histone acetylation. ChIP and
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ChIP-re-ChIP studies show docking of GOF p53 on Sp1 as well as increased binding of Sp1 and
CBP on the EGFR promoter.

Materials and Methods.
Cells. H1299 (ATCC; Manassas, VA), KNS-62, VMRC (JCRB Cell Bank; Osaka,
Japan), H1975, H23, H596, H1048, H1437, H1573, H1793, H2405, and ABC1 (ATCC) cell
lines were all purchased from commercial sources and were maintained in media as suggested by
the suppliers. Methods for lipofection, nucleofection, and generation of stable transfectants were
as described (160, 231, 232). Clones were isolated using puromycin selection at 1µg/ml.
Generation of H1299 cells expressing GOF p53 mutants. To determine the influence
of the transactivation domains on mutant p53-mediated transactivation, we have constructed 3
amino acid substitution mutants: p53-R273H (L22Q/W23S) using the Quikchange mutagenesis
kit (Agilent; Santa Clara, CA), and expressed these p53 mutants in H1299 cells. Multiple clones
were isolated with p53 expression equivalent to that of p53-R273H alone. We used these clones
in comparison with vector transfected cell clones for our assays. We have also used H1299 cells
expressing p53-R273H as described earlier (135).
EGFR promoter transient assays.

The EGFR promoter-luciferase construct was

obtained from Active Motif (Carlsbad, CA). The EGFR expression plasmid was created by
cloning the EGFR cDNA sequence into the pWZL Hygro plasmid purchased from Addgene
(Cambridge, MA). Transient transfection was performed with 500ng of promoter and 1ug of
expression plasmid using Lipofectamine3000 (Invitrogen; Grand Island, NY) following the
manufacturer’s instructions. Luciferase analysis was carried out using the dual luciferase assay
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system (E1500) according to the manufacturer’s instructions (Promega; Madison, WI). Both
transfection and luciferase assay were performed in triplicate as described previously (232).
siRNA Transfection.

siRNAs were nucleofected into H1299 cells expressing p53-

R273H or vector control following the manufacturer's instructions (Lonza; Walkersville, MD).
Sequences used to target individual transcription factors were as follows: siCBP: 5'UUGAGGAAUCAACAGCCGCtt-3'

(233),

GCAAAGUGUGUAACGGAAUAGGUAUtt-3

siEGFR:
'(234),

siEts1:

5'5'-

ACUUGCUACCAUCCCGUACtt-3 '(235), sip63: 5'-AAAGCAGCAAGUUUCGGACAGtt-3
(236)', siSp1: 5'-GGUAGCUCUAAGUUUUGAUtt-3' (237), and siScrambled (control): 5'CAUGUCAUGUGUCACAUUCtt-3 '(238).
Growth assays. Growth assays were carried out as described by us earlier with slight
modifications (135). Cells were plated at a density of 50,000 cells/6cm dish in triplicate for five
time points, harvested after incubation with trypsin and counted using a Coulter Counter
(Beckman).

For siRNA treatment of cells, siRNA transfection was carried out for two

consecutive days before starting the growth assay. All experiments were done in triplicate.
Xenograft assay.

Nu/J (Nude, Jackson Labs; Bar Harbor, ME) or NOD.CB17-

Prkdcscid/NcrCrl (Scid, Charles River Labs; Raleigh, NC) mice were used for the tumorigenicity
studies. Mice were injected with 1x107 cells subcutaneously on the flanks and tumors allowed to
grow to a maximum size of 1cm, measuring periodically as described before (232). Two
different clones of cells were used to rule out clonal variations. For the xenograft assays where
transfections were done prior to injection, we counted the cells after transfection at the day of
injection (48-72 h post transfection).
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Western blotting. Immunoblotting was carried out as described earlier (135). Briefly,
for a typical Western blot we have prepared extracts in Promega Lysis Buffer (Promega). For
Western blots to detect phosphorylated proteins, we have prepared the extracts in RIPA buffer
(see below) with the addition of phosphatase inhibitors. p53 was detected using the p53 antibody
PAb 1801 (93), EGFR and Erk2 antibodies were from Santa Cruz Biotechnology (Dallas, TX)
(sc-03 and sc-154 respectively), phospho-EGFR and phospho-Erk were from Cell Signaling
(Danvers, MA) (2234 and 4370 respectively); transcription factors (TFs) were detected using
respective antibodies from Santa Cruz Biotechnology: CBP (sc-369), Ets-1 (sc-350), p63 (sc8431), and Sp1 (sc-59). Westerns blots were developed by the ECL method (GE Healthcare;
Piscataway, NJ).
Tumor RNA analysis and p53 sequencing. Tumor RNAs were provided by the Tissue
and Data Acquisition and Analysis Core repository under an Institutional Review Board
approved protocol; cDNAs were prepared using the Superscript III cDNA synthesis kit
(Invitrogen)

and

QPCR

performed

using

primers

specific

for

EGFR

(F:

AAGTGTAAGAAGTGCGAAGG-3’ and R: 5'-GGAGGAGTATGTGTGAAGGA-3').

5’The

degree of expression was quantified using a relative standard curve and normalized to GAPDH
(F: 5'-GTCAACGGATTTGGTCGTATT-3’ and R: 5'-GATCTCGCTCCTGGAAGATGG-3')
corresponding to the cDNA batch. The p53 gene is sequenced following the method described
previously (160). Whenever a mutation was found, a new PCR reaction was performed and
fragment re-sequenced to verify sequence information obtained previously. The EGFR levels in
the two populations of tumors, one with WT p53 and one with mutant p53, were compared and
found to be different with a statistically significant difference based on the student t-test.
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Chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP) assays were
performed as described earlier (135). Antibodies used for ChIP were: p53 (DO1: sc-126 and FL393: sc-6243, Santa Cruz), acetylated histone H3 that recognizes acetylated lysine at positions 9
and 14 (17-615, Millipore; Billerica, MA), total histone H3 (06-755, Millipore), TFs (CBP (sc369), Ets-1 (sc-350), p63 (sc-8431), Sp1 (sc-59), and USF1 (sc-229), Santa Cruz Biotechnology)
and IgG (normal mouse: sc-2025 and normal rabbit: sc-2027, Santa Cruz). Quantitative PCR
(QPCR) was used to quantify precipitated DNA using promoter specific primers. The following
primers were used: GAPDH ChIP (F: 5'-GTATTCCCCCAGGTTTACAT-3' and R: 5'TTCTGTCTTCCACTCACTCCT-3'), EGFR ChIP (F: 5'-CCCGCGCGAGCTAGACGTCC-3'
and

R:

5'-GCTCGCTCCGGCTCTCCC-3'),

EGFR

ChIP

set

2

(F:

5'-

ACTATGAAGGCTGTTGTCTC-3' and R: 5'-ACAACAGTGGAACATAAAAT-3'), EGFR
ChIP set 3 (F: 5'-TCTGTGTTTCTACGGACTGC-3' and R: 5'-ATGTTTGTGCCTGGGTCT-3'),
and

EGFR

ChIP

set

4

(F:

TTGGCCAAAAGAAACTGAG-3').

5'-AAAGATGTAAGGTTGCTCCC-3'

and

R:

5'-

ChIP-re-ChIP was performed following the method

described (239) by incubating equal amounts of extracts with p53 and IgG antibodies overnight
and then incubating with BSA and sonicated salmon sperm saturated protein A agarose beads for
one hour at 4°C. The DNA-protein-antibody complexes were then washed once with RIPA
(150mM NaCl, 50mM Tris pH8, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40), once with
High Salt Buffer (500mM NaCl, 50mM Tris pH 8, 0.1% SDS, 1% NP-40), once with LiCl
Buffer (250mM LiCl, 50mM Tris pH 8, 0.5% sodium deoxycholate, 1% NP-40), and once with
1X TE. DNA-protein complexes were eluted from the protein A agarose beads by incubation at
37°C for 30min in 10mM DTT in 1X TE. Eluants were then incubated with the indicated second
antibody overnight, and BSA and sonicated salmon sperm saturated protein A agarose beads
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were added for one hour at 4°C the following day. The DNA-protein-antibody complexes were
then washed once with RIPA, once with High Salt Buffer, once with LiCl Buffer, and once with
1X TE. DNA-protein complexes were eluted at 65°C overnight in fresh elution buffer (20%
SDS, 10mM DTT, 100mM NaHCO3), RNase and proteinase K digested, phenol/chloroform
extracted, and QPCR was performed with specific primers.
Immunoprecipitation assays. Co-immunoprecipitation (IP) of proteins as an indication
of protein-protein interactions were carried out as described earlier (240, 241).

Briefly,

immunoprecipitations were carried out as follows: cells were washed with 1X PBS and harvested
in NP-40 Buffer (50mM Tris pH 7.5, 150mM NaCl, 2mM EDTA, 0.5% NP-40 supplemented
with PMSF and protease inhibitors). Cells were lysed for 30min on ice and passaged through a
27 G needle three times. Lysates were centrifuged and protein concentrations were determined
using the BCA Protein Assay Kit (Thermo Scientific; Waltham, MA). Equal protein amounts
were used for IP. Protein extracts were precleared with protein A agarose rocking at 4°C for one
hour. The extract/bead mix was centrifuged and the supernatant was transferred to new tubes.
Extracts were then incubated with an antibody against p53 (PAb 421) or CBP (sc-369, Santa
Cruz) and protein A agarose beads while rocking at 4°C overnight. The following morning the
extract/bead/antibody mix was centrifuged and the beads were washed three times with NP-40
Buffer. The buffer was removed and equal volume 2XLLB was added and boiled for ten
minutes. Extracts were then run in a PAGE gel. Additionally, a small aliquot of the IP
supernatant was set aside and run in a gel to show the loading control.
Cell migration assays. Cell migration was determined by wound closure assays
described previously (125). Briefly, cells were trypsinized, counted, plated in both chambers of
tissue culture inserts (Ibidi GmbH, Martinsried, Germany), and then grown to confluence. The
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insert was removed, and the distance across the cell-free zone measured (Axiovision software;
Carl Zeiss Microimaging, Thornwood, NY). Cultures were returned to the incubator, allowed to
migrate for 8h, and the width of the cell-free zone re-measured. Migration rate was determined
by subtraction of the final measurement of distance from the initial measurement, divided by
time.
Statistical Analysis. All statistical analyses were calculated using the student's t-test.
Data was considered significant if the p-value was below 0.05.

Experimental Results.
Tumor-derived gain-of function mutant p53 binds on the upstream region of the
EGFR gene and induces histone acetylation. In order to decipher the mechanism of activation
of gene expression by GOF p53 we first identified promoter sequences bound by GOF p53R273H in H1299 cells expressing p53-R273H by performing ChIP-Seq [to be communicated
separately, (242)]. In this analysis, we identified EGFR as a candidate gene whose promoter is
bound by GOF p53. Figure 17A shows mutant p53 (R273H) ChIP-Seq driven peak analysis of
mutant binding on the EGFR promoter with Figure 17B giving the sequence where maximal
mutant p53 binding occurs (indicated by brackets surrounding the peaks). Some of the known
TF binding sites are identified in the sequence. We verified mutant p53 binding on the promoter
region of the EGFR gene by ChIP assays followed by QPCR (Figure 17C). We have also carried
out ChIP assays with an antibody against acetylated histone H3 (AcH3) (Figure 17D). Figure
17D shows increased binding of K9/K14 acetylated histone H3 to the EGFR promoter upon
expression of mutant p53. It is possible that p53-R273H binds to one or more of the TFs
indicated (Figure 17B) and gets nucleated on the promoter, thereby leading to increased
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Figure 17. p53 and AcH3 ChIP sequence peaks on EGFR gene upstream sequences and
QPCR verification of ChIP on the EGFR promoter. Details of ChIP seq analysis and their
verifications have been previously (150). A. The peaks representing areas under which maximal
p53-R273H binding occurs as apparent by next generation sequence analysis (242). B. Sequence
of the major peak (shown above red brackets in A) where mutant p53 binding occurs along with
some of the prominent TF binding sites. C and D. ChIP assay results showing p53-R273H and
AcH3 binding to the EGFR promoter. E. ChIP assay result showing total histone H3 binding to
the EGFR promoter. Asterisks indicate a p-value of less than 0.05.
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AcH3 binding on the EGFR promoter. Figure 17E shows a marginal increase of total histone H3
binding to the promoter, strengthening the case for mutant p53 causing an enhanced amount of
acetylated histone H3 binding to the EGFR promoter.
Tumor-derived gain-of function mutant p53 induces expression of the EGFR gene.
Once we found that mutant p53 binds to the EGFR promoter region, coupled with the knowledge
that mutant p53 also transactivates the EGFR promoter (198, 228), we tested whether H1299
cells expressing p53-R175H and -R273H show higher levels of EGFR mRNA compared to
vector transfected cells. We prepared RNA from these cells and determined EGFR mRNA
levels in samples prepared from two individual clones per transfection. RT-QPCR data shown in
Figure 18 demonstrates that EGFR expression is up-regulated by the p53 mutants in each case in
multiple stable clones. Figure 18B shows an example of a Western blot with higher level of
EGFR in H1299 cells expressing p53 mutants.
EGFR is a target of GOF p53. Next, we wanted to determine if EGFR behaves as a
mutant p53 inducible gene in lung cancer cells expressing endogenous GOF p53. Thus, we
generated p53 knocked-down derivatives from lung cancer cells H1975 (p53-R273H) and KNS62 (p53-R249S) using lentiviral vectors carrying p53 shRNA. Figure 19 indicates knock-down
of the endogenous p53 in stable clones of H1975 and KNS-62 cell lines and shows that the
EGFR level is reduced upon mutant p53 knockdown consistent with EGFR being a mutant p53
target gene. Figure 19B shows the results of RT-QPCR experiments to assay for EGFR levels in
the cell clones generated (as shown in Figure 19A).
Since GOF p53 transactivates the EGFR promoter and induces EGFR expression, we
tested whether it results in enhanced phosphorylation of EGFR, which is indicative of the
activation of EGFR pathway (229). We tested the level of these proteins in H1299 cells
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Vector

p53-R175H p53-R273H

Figure 18. Gain-of-function mutant p53 up-regulates expression of EGFR in H1299 lung
cancer cells. H1299 cells have been stably transfected to express p53 mutants -R175H and R273H (or vector alone). A. RT-QPCR was used to assay for EGFR levels in different cell
clones. The data presented show that GOF p53 up-regulates EGFR mRNA expression.
Different cell clones are indicated by clone numbers. Experiments were done in technical
triplicates. Asterisks indicate a p-value of less than 0.05. B. Example of Western analysis
showing EGFR and mutant p53 levels in different cell clones.
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Figure 19. p53 knock-down in H1975 and KNS-62 cells reduces EGFR levels. A. Western
blot showing phospho-EGFR, EGFR, p53, and Erk2 levels in H1299 cells expressing either an
empty vector or the p53 mutant R273H as well as different cell clones used generated by
recombinant lentiviruses expressing p53 shRNA or control GFP shRNA in H1975 and KNS-62
cells. B. RT-QPCR data for EGFR in different cell lines under study. Different cell clones are
indicated by clone numbers. Experiments were done in technical triplicates.
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expressing p53-R273H (or vector control) as well as H1975 and KNS-62 cells p53 knock-down
(and GFP knock-down control). Data shown in Figure 19A shows that p53-R273H led to an
increase of phospho-EGFR. These data are corroborated by our observations in p53 knock-down
cells.
Lung tumor cells expressing mutant p53 show higher EGFR levels.

Since we

observed that mutant p53 up-regulates EGFR expression (see above), we tested if this is also true
for other lung cancer cell lines and human lung tumors expressing mutant p53. Figure 20A
shows p53 and EGFR protein levels and Figure 20B shows EGFR mRNA levels in different lung
cancer cell lines. Figure 20C depicts EGFR mRNA levels of different human lung tumors
collected in Virginia Commonwealth University's cancer tissue repository. On average, there
was more EGFR expression in samples with mutant p53 versus samples with WT p53 (average
2.1-fold, p-value 0.03), corroborating our cell culture data that mutant p53 up-regulates EGFR
expression. Thus, overall there is an increased expression of EGFR in human lung tumors with
mutant p53.
Lung cancer cells with endogenous GOF p53 are addicted to mutant p53. We tested
whether reduction of p53 would cause significant reduction in oncogenic functions of lung
cancer cells as measured by tumorigenicity in immunodeficient mice. Thus, we performed
tumorigenicity assays in nude or SCID mice as described in Materials and Methods. Figure 21A
shows that p53 knock-down results in remarkable reduction of tumorigenicity, demonstrating
that these lung cancer cells are addicted to mutant p53 for effective tumor formation.
Reduction of mutant p53 and EGFR in lung cancer cells retards tumorigenicity
growth rate and cell motility.

To determine the effect of reducing expression of the

endogenous mutant p53 in the H1975 and KNS-62 cell lines, we performed tumorigenicity
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Figure 20. Lung tumor cells expressing mutant p53 show higher EGFR levels. A. EGFR
levels in various lung cancer cell lines. Western blot analysis of protein extracts of different
lung cancer cell lines were assayed by immunoblot analysis. Many of these lines expressing
mutant p53 also express higher levels of EGFR. B. EGFR mRNA levels in the lung cancer cell
lines presented in A. C. RT-QPCR of EGFR levels in lung tumors. Experiments were done in
technical triplicates as described in the text.
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assays in nude mice where the stable knockdown cell clones were subcutaneously injected. We
then wanted to test whether reduction of p53 can be mimicked by EGFR knock-down in terms of
reduction of oncogenicity as measured by tumorigenicity as well as proliferation and motility
rate of lung cancer cells. Thus, we performed growth assays as described in Materials and
Methods. Similarly, we transiently transfected H1975 cells with EGFR siRNA (or scrambled
siRNA) and performed nude mice tumorigenicity and cell growth assays. Tumorigenicity data
shown in Figure 21B indicate a drastic effect on the tumor growth of H1975 cells suggesting a
strong dependence of the growth of the tumor cells on EGFR even when GOF p53 is present.
Data shown in Figures 21C show that knock-down of either p53 or EGFR reduced the growth
rate significantly. This result suggests the possibility that GOF p53 regulates cell growth, at least
in part, through EGFR expression. In parallel, we performed wound closure assays to determine
the impact of reducing GOF p53 and EGFR on cell motility. As shown in Figures 21E and 21F
respectively, EGFR and GOF p53 knockdown resulted in a decrease in cell motility.
We hypothesize that GOF p53 may execute (some of) its oncogenic function via the
EGFR pathway; if that is true, then the defects encountered by knock-down of GOF p53 should
be compensated by EGFR overexpression in those cells.

Therefore, we tested whether EGFR

overexpression can restore the growth and tumorigenicity defect encountered by knock-down of
GOF p53. Figures 21D and 21G show that expression of EGFR by transfection of H1975 (p53R273H) p53 knock-down cells with an EGFR expression plasmid compensates for the reduced
growth rate and, more importantly, tumorigenicity, respectively, in nude mice. This suggests
that EGFR plays a crucial role in mediating the effects of the mutant p53 GOF pathway.
TFs are involved in inducing binding of acetylated histone H3 on the EGFR
promoter. In order to decipher the mechanism used by GOF p53 in inducing upregulation of
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Figure 21. Reduction of mutant p53 and EGFR in lung cancer cells retards tumorigenicity,
growth rate and cell motility. A. H1975 and KNS-62 cell clones stably expressing shRNA
against p53 were injected into nude (H1975) or SCID (KNS-62) mice. B. H1975 lung cancer
cells were transfected with siRNA targeting EGFR and subsequently injected into nude mice. C.
(i) Growth assay of H1975 cells knocked-down for p53 (and control) generated by recombinant
lentivirus expressing p53 shRNA. (ii) Growth rate of H1975 cells depends on the EGFR level.
H1975 cells were transfected with control or EGFR-specific siRNA. Asterisks indicate a p-value
of less than 0.05. D. H1975 p53 knock-down cells were transfected with an EGFR expression
plasmid to compensate for the EGFR expression loss, and growth assays were performed.
Asterisks indicate a p-value of less than 0.05. E. Migration of H1975 after transient transfection
of RNAi against EGFR shows a reduced migration rate. Asterisk indicates a p-value of less than
0.05. F. H1975 cells show a reduction in migration when the endogenous mutant p53 is stably
knocked-down. Asterisk indicates a p-value of less than 0.05. G. H1975 p53 knock-down cells
were transfected with an EGFR expression plasmid to compensate for the EGFR expression loss,
and tumorigenicity (in nude mice) assays were performed. EGFR expression recovers GOF
activity loss observed on knock-down of mutant p53 of H1975 cells. Western blot showing
EGFR levels of a representative experiment is shown. Experiments were done in triplicate.
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EGFR expression, we investigated the transcriptional machinery at the EGFR promoter which
might be positively influenced by GOF p53.

One such mechanism could be to promote

chromatin opening through histone acetylation. To determine which TFs may be involved in
influencing binding of AcH3 on the EGFR promoter, we transfected mutant p53-R273H
expressing cells (and control) with individual siRNAs targeting different TFs (as well as a
nonspecific control), and performed AcH3 ChIP to test if AcH3 binding on the EGFR promoter
has been changed along with decrease in the TF levels. If a particular TF satisfies this criterion,
this would indicate the involvement of that particular TF in the induction of acetylated H3
histone binding to the EGFR promoter. Figure 22A depicts RNAi experimental data showing
that siRNAs against CBP, Ets-1 and Sp1 had significant effects on binding of AcH3 on the
EGFR promoter whereas RNAi against p63 had limited effects. Figure 22B shows immunoblots
depicting reduction of TF levels after treatment with the respective siRNA. Thus, our results
shown in Figure 22 suggest an involvement of Ets1, Sp1 and CBP in the activation of the EGFR
promoter by GOF p53.
Sp1, CBP and Ets1 affect mutant p53 binding on the EGFR promoter. Since the
data presented in Figure 22A indicated the involvement of TFs Ets1, Sp1 and the histone acetyl
transferase (HAT) CBP, we wanted to test whether these factors are also required for interaction
of mutant p53 on the promoter. To test this, once again we performed TF-directed RNAi
experiments and carried out ChIP for mutant p53 to determine if lowering the levels of any of
these TFs impacts mutant p53 binding. Figure 22C shows that although nonspecific siRNA did
not affect the level of TFs or the binding of mutant p53 on the EGFR promoter, siRNA directed
against Sp1, Ets1 and CBP indeed drastically inhibited the interaction of p53-R273H with the
EGFR promoter. Figure 22D shows that the individual transcription factor expression levels

70

Figure 22. TFs are involved in inducing binding of acetylated histone H3 and p53 on the
EGFR promoter. A. AcH3 ChIP analysis was performed on H1299 cells expressing p53R273H (or vector alone) transfected with RNAi against TFs suspected of binding to the EGFR
promoter (or scrambled siRNA). Normalized values for each siRNA treatment were divided by
the normalized IgG value to calculate fold binding over IgG. The vector was then set to 1 in
each set to be able to compare AcH3 binding between the different transcription factor
knockdowns. Asterisks indicate a p-value of less than 0.05. B. Western blot shows extent of
knock-down of different TFs levels. C. ChIP assays to determine the extent of TF-mediated p53
binding on the EGFR promoter. H1299 cells expressing p53-R273H (or vector alone) were
transfected with RNAi against Sp1, CBP and Ets1 (or scrambled siRNA). Normalized values for
each siRNA treatment were divided by the normalized IgG value to calculate fold binding over
IgG. The vector was then set to 1 in each set to be able to compare p53 binding between the
different transcription factor knockdowns. Asterisks indicate a p-value of less than 0.05. D.
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Western blot analysis of cells used in C showing the effect of TF siRNA on their expression
levels. E. Western analysis of p53 and EGFR expression in siRNA treated cells used for ChIP in
A and C. F. EGFR mRNA expression in siRNA treated cells used for ChIP in A and C.
Asterisks indicate a p-value of less than 0.005.
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were indeed reduced without changing the level of mutant p53 (Figure 22E). This suggests that
these TFs are involved in nucleating mutant p53 on the promoter. Transcription factor silencing
also affects mutant p53-mediated EGFR transactivation. Through expression analysis after
transfection of different siRNAs we show a reduction of EGFR expression (Figure 22F).
Facilitation of TF interactions on the EGFR promoter. We wanted to determine if
GOF p53 facilitates interaction of one or more TFs on the EGFR promoter. Therefore, we
carried out ChIP assays as described (160) using antibodies against TFs with H1299 cell lines
expressing p53-R273H and vector control. We wanted to determine any difference in interaction
of TFs with the EGFR promoter in the presence of mutant p53. Data in Figure 23A show that
mutant p53 induces an increased interaction of a number of TFs on the EGFR promoter,
suggesting cooperative interactions between these TFs and GOF p53. In vivo GOF p53-TF
interactions were studied by immunoprecipitation analysis using procedures described previously
(240, 243).
Data shown in Figure 23B support GOF p53 interactions with Sp1, Ets1, and CBP.
Mutant p53-transcription factor cooperation is particularly high in cases of Ets1, Sp1 and CBP
suggesting that GOF p53 induces nucleation of CBP on the EGFR promoter thorough Sp1 and
Ets1. It is also possible that mutant p53 may stabilize or activate certain TFs and as a result upregulate EGFR gene expression (Figure 23B).
We next used ChIP-re-ChIP experiments to determine if any of these mutant p53-TF
interactions are occurring on the chromatin itself.

Figure 23C shows ChIP-re-ChIP data

investigating the interaction of CBP and Sp1 and mutant p53 on the promoter, and demonstrates
Sp1 as a strong candidate in multiple assays, while CBP also showed significant interactions on
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Figure 23. GOF p53 facilitates interaction of TFs on the EGFR promoter. A. ChIP of
individual TFs on the EGFR promoter in the presence and absence of GOF p53 shows enhanced
interaction of different TFs on the promoter. Normalized values for each transcription factor
were divided by the normalized IgG value to calculate fold binding over IgG. The vector was
then set to 1 in each set to be able to compare binding between the different transcription factors.
Asterisks indicate a p-value of less than 0.05. B. In vivo interactions between different TFs were
carried out in H1299 cells expressing p53-R273H (or vector alone) without transfection of TFs
by immunoprecipitation analysis. Immunoprecipitation of p53-R273H from mutant p53
expressing cells shows binding of mutant p53 with CBP, Ets1, and Sp1. C. ChIP-re-ChIP assay
showing an increased interaction between mutant p53 and CBP as well as mutant p53 and Sp1.
Antibodies used for the first immunoprecipitation are indicated in the body of the figure, and
antibodies used for the second immunoprecipitation are shown on the X-axis. Asterisks indicate
a p-value of less than 0.05 for CBP and less than 0.005 for Sp1.
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the promoter under the conditions of the assay. These data demonstrate that mutant p53 may
nucleate on the EGFR promoter through Sp1 and, to some extent, CBP.
EGFR transactivation by GOF p53 can withstand mutations in the p53
transactivation domain. To determine if the transactivation domain (TAD) of GOF p53 is
needed for up-regulation of EGFR expression, we stably transfected H1299 cells with p53R273H or p53-R273H (22Q/23S) (or vector alone) and isolated independent cell clones. Figure
24A shows Western blot analysis of EGFR and p53 levels of the clones being used in our assays.
Next, we isolated RNA from each cell clone, and performed quantitative RT-QPCR to determine
the level of EGFR mRNA in the different cell lines. The data presented in Figure 24B show that
the particular TAD mutations did not affect EGFR induction by mutant p53-R273H. To ensure
that our TAD mutants do in fact transactivate the EGFR promoter we performed a transient
transactivation assay and found (Figure 24C) that the presence of TAD mutations do not inhibit
EGFR promoter activation.
TAD mutations differentially affect GOF p53 interactions and binding of acetylated
histones on the EGFR promoter. Since TAD is an important component of the transactivation
machinery and is where TFs have a tendency to contact p53 (244), we wanted to test if TAD
mutations affect transactivation by GOF p53 via effects on mutant p53 binding on the EGFR
promoter and/or effects on histone acetylation. Therefore, we used QPCR to quantitatively
determine the effects of TAD mutations on mutant p53-mediated activation of EGFR
transcription (assayed by RT-QPCR) as well as nucleation of p53-R273H and AcH3 on its
promoters (assayed by ChIP) (Figure 25A). TAD mutations did indeed show a significant
reduction of mutant p53 and TF interactions on the region examined (shown in Figure 17B).
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Figure 24. EGFR transactivation by GOF p53 can withstand mutations in the
transactivation domain of GOF p53. H1299 cells were stably transfected with expression
plasmids containing either the p53 mutant R273H, the p53 TAD mutant R273H (L22Q/W23S),
or vector alone and cell clones were isolated. A. Western blots show expression levels of mutant
EGFR and p53. B. RT-QPCR analysis showing levels of EGFR in different cell lines. Asterisks
indicate a p-value of less than 0.005. C. Luciferase assay showing transactivation of the EGFR
promoter by both p53-R273H as well as p53-R273H 22/23. Asterisks indicate a p-value of less
than 0.05.
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This is accompanied by a reduction of histone H3 acetylation and the data are shown in Figure
25A. Next we looked at the ability of our TAD mutant cell line to recruit transcription factors to
the EGFR promoter. Figure 25B shows a reduction of transcription factor binding that was
similar to the reduction of mutant p53 and histone H3 acetylation binding in Figure 25A at the
region shown in Figure 17B. This suggested to us that mutant p53 with TAD mutations might be
efficiently interacting at one or more different sites other than that shown in Figure 17B. We
have performed ChIP using PCR primers corresponding to sequences spanning different regions
on the EGFR promoter as shown on the schematic. Figure 25D shows data supporting our
hypothesis that mutant p53-R273H and its TAD mutant both interact significantly with multiple
locations on the EGFR promoter (identified by ChIP Seq), although the TAD mutant failed to
interact in the primary site identified by ChIP Seq; these interactions perhaps result in activation
of histone H3 acetylation where TFs are also successfully recruited (Figure 25C). It is possible
that TAD interacts with different sequences of the EGFR promoter region using motifs defined
by amino acids other than those mutated in the present construct (amino acids 22 and 23).

Chapter Summary.
Earlier work has shown that GOF p53 transactivates the EGFR promoter using transient
transfection assays. Microarray and RNA sequencing have also shown up-regulation of EGFR
by mutant p53. Here, we show that lung cancer cells expressing GOF p53 are addicted to mutant
p53; knock-down of p53 in H1975 (p53-R273H) and KNS-62 (p53-R249S) lung cancer cells
causes reduction of tumorigenicity and other GOF properties. Using H1299 cells expressing
p53-R273H we demonstrate that mutant p53 up-regulates epidermal growth factor receptor
(EGFR) expression and activity. Human lung tumors expressing mutant p53 also show higher
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Figure 25. TAD mutations differentially affect GOF p53 interactions and binding of
acetylated histones with the EGFR promoter. A. ChIP assays showing mutations in TAD
alter a majority of interactions of mutant p53 and enhanced binding of acetylated histone H3 to
the EGFR promoter. Normalized values were divided by the normalized IgG. Asterisks indicate
a p-value of less than 0.05. B. ChIP assays showing mutations in TAD alter binding of different
transcription factors to the EGFR promoter. Asterisks indicate a p-value of less than 0.05. C.
ChIP samples in Figure 6B were assayed using a different set of primers on the EGFR promoter
about 1.5kb upstream of set 1 to show mutant p53 and its TAD mutant have a similar binding
pattern at a distant location (as shown in the diagram). N.S. indicates no significant difference.
D. ChIP samples in Figure 6A were assayed using three different sets of primers on the EGFR
promoter about 500bp-1.5kb upstream of set 1 to show mutant p53 and its TAD mutant have a
similar binding pattern at a distant locations. Positions of the primer sets are shown in the figure.
N.S. indicates no significant difference.
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EGFR levels. Knock-down of p53 in H1975 and KNS-62 cells lowers EGFR overexpression;
however, the addiction to GOF p53 can be compensated in H1975 cells by overexpressing
EGFR, suggesting that EGFR is in the GOF p53 pathway and plays a critical role in addiction of
lung cancer cells to GOF p53. Chromatin immunoprecipitation (ChIP) assays show that p53R273H interacts with the EGFR promoter and increases histone H3 acetylation, indicating a
mechanism whereby mutant p53 enhances chromatin opening for improved access to
transcription factors. ChIP and ChIP-re-ChIP studies show docking of GOF p53 on Sp1, leading
to increased binding of Sp1 and CBP on the EGFR promoter. Using a transactivation domain
(TAD) mutant of GOF p53, we show that TAD-mutated GOF p53 is efficient in up-regulating
EGFR. Although TAD mutations cause disruption of mutant p53 interactions at a major binding
site, mutant p53-promoter interactions at multiple sites appear to be responsible for significant
mutant p53-mediated EGFR transactivation capability which suggests multiple contacts of TAD
with transcription factors.
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Discussion
p53 plays a significant role in oncogenesis, whether it is present in the cell as the wildtype or mutant form of the protein. WT p53 has long been shown to be key to maintaining the
integrity of the cell and therefore preventing oncogenesis; meanwhile mutant p53 causes the
acquisition of new oncogenic functions. Both WT and mutant p53 have biological activities that
are dependent on its transcriptional ability, and both proteins have been demonstrated to repress
and activate expression of a number of genes. We and others have shown that expression of
tumor-derived mutant p53 in cells leads to upregulated expression of a set of genes, some of
which are involved in increased cell growth rate, cell motility, tumorigenicity, and loss of
sensitivity to chemotherapeutic drugs (107, 110, 245) as an indicator of GOF activity.
We have suggested earlier that, in the case of H1299 lung carcinoma cells, the
chemoresistance observed by the expression of mutant p53 can be attributed at least in part
through mutant p53-mediated transactivation of the NF-κB2 gene (110). Here, using cancer cell
lines containing endogenous GOF p53, we have demonstrated that the presence of p53 mutants
leads to GOF phenotypes as shown by an increase in cell growth rate, cell motility,
tumorigenicity, and loss of sensitivity to chemotherapeutic drugs (Figures 3-5). We have further
shown that the GOF activities are dependent on the level of NF-κB2 (Figure 6), verifying that
mutant p53-induced GOF functions utilize NF-κB2 to accomplish these phenotypes, at least in
part.
We next examined the mechanism of up-regulation of NF-κB2 by mutant p53 since
transient transcriptional analysis could not detect any mutant p53 response element (Figure 7).
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This was not unexpected as previous studies also failed to detect any (163, 198). Furthermore,
ChIP experiments showed that mutant p53 induces chromatin changes via histone acetylation
that may cause activation of the NF-κB2 promoter (Figure 8). This histone acetylation perhaps
leads to increased interaction of the transcription factor STAT2 to a STAT binding site on the
NF-κB2 promoter which may be the reason for increased NF-κB2 promoter activity in the
presence of mutant p53 (Figure 8). Data also show an interaction of CBP with the NF-κB2
promoter (Figure 8). Since CBP/p300 has histone acetylase activity associated with it, these data
indicate that mutant p53 may be enhancing histone acetylation through the use of CBP/p300.
Interestingly, interactions of CBP/p300 and STAT, p53 and STAT as well as p53 and CBP/p300
have been reported (246-248). Since the data was generated, several reports have been published
illustrating STAT regulation via acetylation (249). In fact, STAT2 was even shown to recruit
HATs and cause transient acetylation of histones even though p300/CBP is not required for
STAT function (248).
With that information in hand, we speculate that the STAT1/STAT2 complex on the
NF-κB2 promoter interacts with CBP/p300 to open up chromatin and pull down mutant p53. We
further speculate that mutant p53 then stimulates further opening up of chromatin via its
interaction with CBP/p300 with a positive feed-back loop.
Earlier, we had suggested that the GOF activities observed in H1299 cells after
expression of mutant p53 can be explained in part by mutant p53’s ability to enhance expression
of NF-κB2 (110). Axl has been identified as another player via microarray analysis of H1299
cells stably expressing different p53 mutants. Axl has previously been implicated in oncogenesis
(206) and is significantly up-regulated by tumor derived p53 mutants in lung cancer cell lines
and human lung tumors (Figures 9 and 10). One interesting and important aspect of Axl being
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up-regulated by p53 mutants is the fact that p53 mutants do not require an intact transactivation
domain for this up-regulation (Figure 9). Thus, this mutant p53 target seems to be a good
candidate gene that is up-regulated by mutant p53 perhaps through interaction with p63/p73
(155). We note that there is a second transactivation subdomain that may contribute to
transactivation, and further studies would need to be performed to investigate the role the second
transactivation domain plays in Axl upregulation by mutant p53.
Using human lung cancer cell lines and lung tumor samples expressing mutant p53 we
demonstrate that expression of GOF mutant p53 induces Axl expression (Figure 10). We found
that knocking down Axl levels by RNAi in H1048 cells led to a decrease in cell motility and
growth rate (Figure 11) while mutant p53 level remained constant. This suggests that GOF
mutant p53 may induce part of its GOF activity via induction of Axl.
We have examined the promoter sequences of Axl and identified several transcription
factor binding sites (Figure 12 top), and have performed transient transcriptional analysis to
determine the mechanism of activation of the promoter by GOF mutant p53. Transient
transfections showed that mutant p53 indeed transactivates the Axl promoter in H1299 cells
(Figure 12), however, our promoter deletion analysis indicated that the p53/p63-binding site
present is not needed for transactivation by mutant p53 in H1299 cells (Figure 13). This shows
that GOF p53 mutants transactivate the Axl promoter without the necessity of p63 binding to the
promoter.
ChIP assay analysis demonstrated that GOF mutant p53 induces histone acetylation at the
Axl promoter (Figure 14A-D) suggesting that mutant p53 causes chromatin modifications on the
promoter indicative of increased transcriptional activity. Transcription factor ChIP analyses
indicated that mutant p53 induced interaction between p300, CREB, and E2F1 on the Axl
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promoter (Figure 16), which suggests their involvement in general in transactivation of Axl by
mutant p53. The observed increased histone acetylation may lead to increased interaction of the
transcription factors p300, CREB, and E2F1 with their binding sites on the Axl promoter, which
then leads to an increase in Axl promoter activity. Since CBP/p300 has histone acetylase activity
associated with it, these data suggest that mutant p53 may be enhancing histone acetylation of
the Axl promoter through the use of CBP/p300. Interestingly, interactions of CBP/p300 and
E2F1 and CREB (250) may further nucleate p300 on the Axl promoter and lead to further
acetylation of histones increasing its promoter activity.
We have demonstrated that there is more mutant p53-mediated activation of the Axl
promoter further away from the transcription start site indicating mutant p53 may bind to an
enhancer-like region to regulate transcription (Figure 15). Further in vivo and in vitro work is
needed to clarify the mechanism of transactivation by mutant p53.
We next examined the mechanism of up-regulation of EGFR expression by GOF p53 and
demonstrated that EGFR is elevated at the mRNA level by GOF p53 in H1299, KNS-62 and
H1975 cells. Through RNAi experiments in H1975 cells we show that reduction of mutant p53
or EGFR levels lowers the proliferation rate of these cells, indicating that both genes are in a
pathway that controls cell proliferation. Since mutant p53 up-regulates EGFR, this also suggests
that this particular GOF activity of mutant p53 is through EGFR up-regulation, at least in part.
This concept has been strengthened further by restoration of GOF activity lost by reduction of
p53 levels on overexpression of EGFR (Figure 21). However, multiple mutant p53 targets have
been identified that may be responsible for induction of proliferation (84, 160, 251). Thus, a
thorough functional-genomic approach is needed to fully understand which genes are required
for different GOF activities.
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We also show that mutant p53 expression leads to enhanced binding of GOF p53 on the
EGFR promoter, and importantly it induces enhanced interaction of TFs on the EGFR promoter
including the HAT, CBP and Sp1 (Figure 23). ChIP for AcH3 indicates enhanced acetylation of
histone H3 in the presence of mutant p53, indicative of induced opening of the chromatin near
the mutant p53 binding site. Thus, the mechanism by which mutant p53 activates EGFR
transcription may depend upon nucleation of mutant p53 that then induces acetylation of histone
H3, opening chromatin and activating transcription.
We examined the contribution of the transactivation domain in transactivation of EGFR
and nucleation of mutant p53 and AcH3 (as assayed by ChIP). Interestingly, mutations in TAD
affected nucleation of mutant p53 and AcH3 at the major binding site (Figure 25) but not
transactivation of EGFR (Figure 24). Since our data show no absolute requirements of integrity
of amino acids at positions 22 and 23, it perhaps points to the possible interactions of TFs
included in extended regions of TAD. However, we showed that transactivation by GOF p53
requires the presence of TAD (198) suggesting an important contribution of TAD in
transactivation. The scanning ChIP QPCR data shown in Figure 25 suggest that the promoter
sequences defined by primer set 1 requires integrity of amino acids 22 and 23 of TAD to be
precise, perhaps through a direct interaction of TFs whereas TAD can contact other regions via
other TAD sequences. It is possible in that case sequences in the second transactivation domain
may prove to be important (244).
It is important to note that we find that mutant p53 induces enhanced interaction of TFs
on the EGFR promoter. It is possible that this results in enhanced binding of CBP/p300 to the
EGFR promoter and consequently higher levels of acetylation of histone H3. This is expected to
impact the chromatin structure in a positive manner, paving the way for a higher rate of
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transcription. In the future, it needs to be ascertained if the information exchange between the
proteins happens while they remain on the promoter or when they are unbound from the DNA.
Involvement of the Sp1 and Ets group of transcription factors and mutant p53 in mutant p53mediated transactivation as a component of its GOF activity has been suggested by us and others
in the past (166, 242, 252).
Since NF-κB2, Axl, and EGFR all show enhanced histone acetylation and transcription
factor binding to their promoters in the presence of GOF p53, it is possible that mutant p53
utilizes a similar mechanism to activate transcription and thus upregulate expression of these
three genes. We have shown that mutant p53 enhances Sp1 and CBP binding for both the Axl
and EGFR promoters, however, the NF-κB2 promoter also has Sp1 binding sites which have not
been explored yet. It would be interesting to know whether we can also see enhanced Sp1
binding in the presence of mutant p53 on the NF-κB2 promoter as well. In addition, Sp1 and
Ets1 are known to interact, and in the case of the EGFR promoter ChIP-reChIP, Sp1 was seen to
interact with mutant p53 at the promoter whereas Ets1 was not (data not shown). In this case, it
is possible that the enhanced Ets1 binding to that particular promoter may be due at least in part
to interaction with Sp1 since there are many more binding sites for Sp1 than Ets1.
The work presented here shows a possible mechanism of up-regulation of mutant p53
target gene expression with the involvement of chromatin modifications. In the case of NF-κB2,
this chromatin modification is brought into action most likely by CBP which is found to be
nucleated on the promoter. As a result of the histone acetylation, we can observe increased
STAT interaction on the promoter that might be the reason for enhanced transcription of the
mutant p53 target, NF-κB2.
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We suggest a model (Figure 26) in which mutant p53 interacts on the target promoters
via interaction with multiple TFs: Ets1, Sp1 and perhaps others (Figure 25). Possibly, GOF p53
docks with Sp1 and CBP. p300/CBP may become involved in the process either because of
direct interaction of p53 and CBP/p300 or through Ets1-CBP/p300 and/or Sp1-CBP/p300
interactions (253-256). Sp1 and Ets1 interactions with CBP/p300 have been suggested to
facilitate acetylation of histones (257, 258). This increased histone acetylation then translates
into chromatin opening and increased transcription.
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Figure 26. Proposed model for GOF p53 nucleating on a target promoter.
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